<SEC-DOCUMENT>0001213900-23-060256.txt : 20230727
<SEC-HEADER>0001213900-23-060256.hdr.sgml : 20230727
<ACCEPTANCE-DATETIME>20230727160232
ACCESSION NUMBER:		0001213900-23-060256
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230724
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230727
DATE AS OF CHANGE:		20230727

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NEUROONE MEDICAL TECHNOLOGIES Corp
		CENTRAL INDEX KEY:			0001500198
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				270863354
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40439
		FILM NUMBER:		231118337

	BUSINESS ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344
		BUSINESS PHONE:		(952) 426-1383

	MAIL ADDRESS:	
		STREET 1:		7599 ANAGRAM DR
		CITY:			EDEN PRAIRIE
		STATE:			MN
		ZIP:			55344

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Original Source Entertainment, Inc.
		DATE OF NAME CHANGE:	20100830
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea182399-8k_neuroone.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:NMTC="http://n1mtc.com/20230724">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02C_US%2DGAAP%2D2023 -->
<!-- Field: Set; Name: xdx; ID: xdx_032_NMTC_n1mtc.com_20230724 -->
<!-- Field: Set; Name: xdx; ID: xdx_04A_20230724_20230724 -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DEntityCentralIndexKey_0001500198 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:EntityCentralIndexKey">0001500198</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="nmtc-20230724.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2023-07-24">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001500198</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-24</xbrli:startDate>
        <xbrli:endDate>2023-07-24</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20230724__20230724_zPvNVwy7Qb7h"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of Earliest Event Reported <span id="xdx_904_edei--DocumentPeriodEndDate_c20230724__20230724_zYGC7GRGg8Ji"><ix:nonNumeric contextRef="AsOf2023-07-24" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">July 24, 2023</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityRegistrantName_c20230724__20230724_zTuTKPGKVEi3"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:EntityRegistrantName">NeuroOne Medical Technologies Corporation</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20230724__20230724_zkYSx5LIphGg"><ix:nonNumeric contextRef="AsOf2023-07-24" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_903_edei--EntityFileNumber_c20230724__20230724_z4jR02tkOD27"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:EntityFileNumber">001-40439</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_904_edei--EntityTaxIdentificationNumber_c20230724__20230724_zwymVR54IAmf"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:EntityTaxIdentificationNumber">27-0863354</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
                                            or other jurisdiction</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission
    File Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS
    Employer<br />
Identification No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_906_edei--EntityAddressAddressLine1_c20230724__20230724_zKGA1aisPeXb"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:EntityAddressAddressLine1">7599 Anagram Dr.</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressCityOrTown_c20230724__20230724_zTqWKifJ77Gk"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:EntityAddressCityOrTown">Eden Prairie</ix:nonNumeric></span>, <span id="xdx_900_edei--EntityAddressStateOrProvince_c20230724__20230724_zHvOJsu4Yvql"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:EntityAddressStateOrProvince">MN</ix:nonNumeric></span> <span id="xdx_90F_edei--EntityAddressPostalZipCode_c20230724__20230724_zp06OF6Fjzh3"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:EntityAddressPostalZipCode">55344</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices and zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_908_edei--CityAreaCode_c20230724__20230724_zLiyNhurgF3g"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:CityAreaCode">952</ix:nonNumeric></span>-<span id="xdx_903_edei--LocalPhoneNumber_c20230724__20230724_zzNiYjTIduda"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:LocalPhoneNumber">426-1383</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Registrant&#8217;s
telephone number including area code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_902_edei--WrittenCommunications_c20230724__20230724_zuikknXkF8Gl"><ix:nonNumeric contextRef="AsOf2023-07-24" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_edei--SolicitingMaterial_c20230724__20230724_zd4LEB4UbwYi"><ix:nonNumeric contextRef="AsOf2023-07-24" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementTenderOffer_c20230724__20230724_zSyG4SXz4edd"><ix:nonNumeric contextRef="AsOf2023-07-24" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_edei--PreCommencementIssuerTenderOffer_c20230724__20230724_zBarAMXszny6"><ix:nonNumeric contextRef="AsOf2023-07-24" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: #CCEEFF">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_907_edei--Security12bTitle_c20230724__20230724_zUXOHK13Y336"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:Security12bTitle">Common Stock, par value $0.001 per share</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_900_edei--TradingSymbol_c20230724__20230724_zSZkNyzQWubj"><ix:nonNumeric contextRef="AsOf2023-07-24" name="dei:TradingSymbol">NMTC</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
    <span id="xdx_90E_edei--SecurityExchangeName_c20230724__20230724_zlV82JOKVjc9"><ix:nonNumeric contextRef="AsOf2023-07-24" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</span> </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
Growth Company <span id="xdx_900_edei--EntityEmergingGrowthCompany_c20230724__20230724_zkNijR2re0Zb"><ix:nonNumeric contextRef="AsOf2023-07-24" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; font-size: 1pt; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
1.01 Entry into a Material Definitive Agreement.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b>On July 24, 2023, NeuroOne Medical Technologies Corporation (the &#8220;Company&#8221;), entered into an Underwriting Agreement (the
&#8220;Underwriting Agreement&#8221;) with The Benchmark Company, LLC, as underwriter (the &#8220;Underwriter&#8221;), relating to the
issuance and sale of 5,250,000 shares of the Company&#8217;s common stock, par value $0.001 per share, at a price to the public of $1.00
per share. In addition, under the terms of the Underwriting Agreement, the Company granted the Underwriter an option, exercisable for
30 days, to purchase up to an additional 787,500 shares of common stock on the same terms (&#8220;the Overallotment Option&#8221;). The
offering closed on July 27, 2023, and the Company completed the sale and issuance of an aggregate of 6,037,500 shares of its common stock,
including the exercise in full of the Overallotment Option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
net proceeds to the Company from this offering will be approximately $5,214,875 after deducting underwriting discounts and other offering
expenses payable by the Company. The Company intends to use the net proceeds from this offering to: (i) support the commercial launch
of the EVO Seeg electrode with Zimmer Biomet, (ii) support the FDA submission for the OneRF ablation system and (iii) complete the design
of a novel drug delivery electrode, among other general corporate purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>The
Underwriting Agreement contains customary representations, warranties, covenants and agreements of the Company, indemnification obligations
of the Company and the Underwriter, including liabilities under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;),
other obligations of the parties and termination provisions. In addition, pursuant to the terms of the Underwriting Agreement, the Company
and, pursuant to separate lock-up agreements, its executive officers and directors may not, without the prior written approval of the
Underwriter, subject to limited exceptions, offer, sell, agree to sell, directly or indirectly, or otherwise dispose of any shares of
common stock or any securities convertible into or exchangeable for shares of common stock for a period of 90 days following the offering.
The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and
as of specific dates, were only for the benefit of the parties to such agreement and may be subject to limitations agreed upon by the
contracting parties. The Underwriting Agreement is filed as Exhibit 1.1 hereto and the description of the terms of the Underwriting Agreement
is qualified in its entirety by reference to such exhibit.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
offering was made pursuant to an effective registration statement on Form S-3 (File No. 333-256830), previously filed with the Securities
and Exchange Commission, and the related prospectus supplement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the opinion of Honigman LLP relating to the legality of the issuance and sale of the shares in the offering is attached as Exhibit
5.1 hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item
8.01 Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b></b>On July 24, 2023, the Company issued a press release announcing that the Company had commenced the offering. On July 25, 2023, the
Company issued a press release announcing the pricing of the offering. The press releases are attached as Exhibits 99.1 and 99.2 hereto,
respectively, and are incorporated herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 9.01</b></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Financial Statements and Exhibits.</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(d)
Exhibits</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top; width: 9%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 90%"><a href="ea182399ex1-1_neuroone.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Underwriting Agreement, dated July 24, 2023, between NeuroOne Medical Technologies Corporation and The Benchmark Company, LLC</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ea182399ex5-1_neuroone.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Opinion of Honigman LLP</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ea182399ex5-1_neuroone.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consent of Honigman LLP (included in Exhibit 5.1)</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ea182399ex99-1_neuroone.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated July 24, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.2</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ea182399ex99-2_neuroone.htm"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated July 25, 2023</span></a></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; vertical-align: top">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">Cover Page Interactive Data File (embedded with Inline XBRL document).</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NEUROONE
    MEDICAL TECHNOLOGIES CORPORATION </b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 60%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    July 27, 2023</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 37%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    David Rosa</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Rosa</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 6pt; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjV0KwjAQhE/QOyx5ltpG6k8fLSpiFSkivga7lWCbLZv4dyRvaWwRl4VlmflmhBiIFS11jQyneZHDAZu2Vg6hwAoZzRm9I1tvUvC3wIu2jpVx3fsDM/IMeiYJ45nyQme9a4tlCtFkKMdDOYJIpskU9lsRfPWMTKVLNE6rGpQpYc/Uskan+NUnHNSTDDWvruqIbDWZFOIw6uU3yCiWsKO7ehBfLeR5JoJBN4FYMd3ab83NOmpgUWPju2yP/jf4ACG5SVk= -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ea182399ex1-1_neuroone.htm
<DESCRIPTION>UNDERWRITING AGREEMENT, DATED JULY 24, 2023, BETWEEN NEUROONE MEDICAL TECHNOLOGIES CORPORATION AND THE BENCHMARK COMPANY, LLC
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 1.1<I></I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B><I>EXECUTION VERSION</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>5,250,000 Shares<SUP>1</SUP></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NEUROONE MEDICAL TECHNOLOGIES CORPORATION</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Common Stock, par value $0.001 per share</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNDERWRITING
AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">July 24, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Benchmark Company, LLC <BR>
150 East 58th Street,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">17th Floor New York <BR>
New York 10155</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">NeuroOne Medical Technologies
Corporation, a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>) proposes to sell to The Benchmark Company, LLC (the <B><I>&ldquo;Underwriter&rdquo;</I></B>)
an aggregate of 5,250,000 shares (the <B><I>&ldquo;Firm Shares&rdquo;</I></B>) of Common Stock, par value $0.001 per share (the <B><I>&ldquo;Common
Stock&rdquo;</I></B>), of the Company. The Company has also granted to the Underwriter an option to purchase up to 787,500 additional
shares of Common Stock on the terms and for the purposes set forth in Section 3 hereof (the <B><I>&ldquo;Option Shares&rdquo;</I></B>).
The Firm Shares and any Option Shares purchased pursuant to this Underwriting Agreement (this <B><I>&ldquo;Agreement&rdquo;</I></B>) are
herein collectively called the <B><I>&ldquo;Securities</I></B><I>.<B>&rdquo;</B></I></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Company and the Underwriter
hereby confirm their agreement with respect to the sale of the Securities by the Company to the Underwriter as follows:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">1. <B><I>Registration
Statement and Prospectus</I></B>. The Company has prepared and filed with the Securities and Exchange Commission (the <B><I>&ldquo;Commission&rdquo;</I></B>)
a registration statement on Form S-3 (File No. 333-256830) under the Securities Act of 1933, as amended (the <B><I>&ldquo;Securities Act&rdquo;
</I></B>or the <B><I>&ldquo;Act&rdquo;</I></B>), and the rules and regulations (the <B><I>&ldquo;Rules and Regulations&rdquo;</I></B>)
of the Commission thereunder, and such amendments to such registration statement as may have been required to the date of this Agreement.
Such registration statement has been declared effective by the Commission. Each part of such registration statement, including the amendments,
exhibits and any schedules thereto, the documents incorporated by reference therein pursuant to Item 12 of Form S-3 under the Securities
Act and the documents and information otherwise deemed to be a part thereof or included therein by Rule 430B under the Securities Act
(the <B><I>&ldquo;Rule 430B Information&rdquo;</I></B>) or otherwise pursuant to the Rules and Regulations, as of the time the Registration
Statement became effective, is herein called the <B><I>&ldquo;Registration Statement.&rdquo; </I></B>Any registration statement filed
by the Company pursuant to Rule 462(b) under the Securities Act is called the <B><I>&ldquo;Rule 462(b) Registration Statement&rdquo;</I></B>
and, from and after the date and time of filing of the Rule 462(b) Registration Statement, the term <B><I>&ldquo;Registration Statement&rdquo;</I></B>
shall include the Rule 462(b) Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 25%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid"><SUP>&nbsp;</SUP></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><SUP>1</SUP></TD><TD STYLE="text-align: justify">Plus an option to purchase up to <FONT STYLE="font-size: 10pt">787,500
</FONT>additional shares.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The prospectus in the form
in which it has most recently been filed with the Commission on or prior to the date of this Agreement is herein called the <B><I>&ldquo;Base
Prospectus.&rdquo;</I></B> Each preliminary prospectus supplement to the Base Prospectus (including the Base Prospectus as so supplemented),
that describes the Securities and the offering thereof, that omitted the Rule 430B Information and that was used prior to the filing of
the final prospectus supplement referred to in the following sentence is herein called a <B><I>&ldquo;Preliminary Prospectus.&rdquo;</I></B>
Promptly after execution and delivery of this Agreement, the Company will prepare and file with the Commission a final prospectus supplement
to the Base Prospectus relating to the Securities and the offering thereof in accordance with the provisions of Rule 430B and Rule 424(b)
of the Rules and Regulations. Such final supplemental form of prospectus (including the Base Prospectus as so supplemented), in the form
filed with the Commission pursuant to Rule 424(b), is herein called the <B><I>&ldquo;Prospectus.&rdquo;</I></B> Any reference herein to
the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to include the documents incorporated by reference therein
pursuant to Item 12 of Form S-3 under the Securities Act as of the date of such prospectus.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For purposes of this Agreement,
all references to the Registration Statement, the Rule 462(b) Registration Statement, the Base Prospectus, any Preliminary Prospectus,
the Prospectus or any amendment or supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant
to its Electronic Data Gathering, Analysis and Retrieval System or any successor system thereto (<B><I>&ldquo;EDGAR&rdquo;</I></B>). All
references in this Agreement to financial statements and schedules and other information which is &ldquo;contained,&rdquo; &ldquo;included&rdquo;
or &ldquo;stated&rdquo; in the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus (or other references
of like import) shall be deemed to mean and include all such financial statements and schedules and other information which is incorporated
by reference in or otherwise deemed by the Rules and Regulations to be a part of or included in the Registration Statement, the Base Prospectus,
any Preliminary Prospectus or the Prospectus, as the case may be; and all references in this Agreement to amendments or supplements to
the Registration Statement, the Base Prospectus, any Preliminary Prospectus or the Prospectus shall be deemed to mean and include the
subsequent filing of any document under the Securities Exchange Act of 1934, as amended (the <B><I>&ldquo;Exchange Act&rdquo;</I></B>),
which is incorporated by reference therein or otherwise deemed by the Rules and Regulations to be a part thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">2.
</FONT><B><I>Representations and Warranties of the Company</I></B><FONT STYLE="font-style: normal; font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a) <I><U>Representations
and Warranties of the Company</U></I>. The Company represents and warrants to, and agrees with, the Underwriter as follows:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(i) <I><U>Registration
Statement and Prospectuses</U></I>. No order preventing or suspending the use of the Registration Statement, any Preliminary Prospectus
or the Prospectus (or any supplement thereto) has been issued by the Commission and no proceeding for that purpose has been initiated
or is pending or, to the knowledge of the Company, threatened by the Commission. As of the time each part of the Registration Statement
became or becomes effective (including each deemed effective date with respect to the Underwriter pursuant to Rule 430B or otherwise under
the Securities Act), such part conformed or will conform in all material respects to the requirements of the Act and the Rules and Regulations.
Upon the filing or first use within the meaning of the Rules and Regulations, each Preliminary Prospectus and the Prospectus (or any supplement
to either) conformed or will conform in all material respects to the requirements of the Act and the Rules and Regulations. The Registration
Statement has become effective under the Securities Act and the Company, as of the date of this Agreement, has not filed a post-effective
amendment to the Registration Statement. The Company has complied to the Commission&rsquo;s satisfaction with all requests of the Commission
for additional or supplemental information. No stop order suspending the effectiveness of the Registration Statement or any part thereof
is in effect and no proceedings for such purpose have been instituted or are pending or, to the knowledge of the Company, are threatened
by the Commission. All references in this Agreement to the Company&rsquo;s &ldquo;knowledge&rdquo; shall mean the actual knowledge of
the Company&rsquo;s Chief Executive Officer or Chief Financial Officer after reasonable investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(ii) <I><U>Accurate
Disclosure</U></I>. Each Preliminary Prospectus, at the time of filing thereof or the time of first use within the meaning of the Rules
and Regulations, did not contain an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading. Neither the Registration
Statement nor any amendment thereto, at the effective time of each part thereof, at the First Closing Date (as defined below) or at the
Second Closing Date (as defined below), contained, contains or will contain an untrue statement of a material fact or omitted, omits or
will omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the
Time of Sale (as defined below), neither (A) the Time of Sale Disclosure Package (as defined below) nor (B) any issuer free writing prospectus
(as defined below), when considered together with the Time of Sale Disclosure Package, contained an untrue statement of a material fact
or omitted to state a material fact necessary in order to make the statements therein, in light of the circumstances under which they
were made, not misleading. Neither the Prospectus nor any supplement thereto, as of its issue date, at the time of any filing with the
Commission pursuant to Rule 424(b) of the Rules and Regulations, at the First Closing Date or at the Second Closing Date, contained, contains
or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make
the statements therein, in light of the circumstances under which they were made, not misleading. The representations and warranties in
this Section 2(a)(ii) shall not apply to statements in or omissions from any Preliminary Prospectus, the Registration Statement (or any
amendment thereto), the Time of Sale Disclosure Package or the Prospectus (or any supplement thereto) made in reliance upon, and in conformity
with, written information furnished to the Company by you, or by the Underwriter through you, specifically for use in the preparation
of such document, it being understood and agreed that the only such information furnished by the Underwriter consists of the information
described as such in Section 6(e).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Each reference to an <B><I>&ldquo;issuer free
writing prospectus&rdquo; </I></B>herein means an issuer free writing prospectus as defined in Rule 433 of the Rules and Regulations.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B><I>&ldquo;Time of Sale Disclosure Package&rdquo;</I></B>
means the Preliminary Prospectus dated July 24, 2023, any free writing prospectus set forth on Schedule I and the information on Schedule
III, all considered together.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each reference to a <B><I>&ldquo;free writing prospectus&rdquo;</I></B>
herein means a free writing prospectus as defined in Rule 405 of the Rules and Regulations.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&ldquo;Time of Sale&rdquo;</I></B> means 9:10 pm (Eastern time)
on the date of this Agreement.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iii) <I><U>Issuer
Free Writing Prospectuses</U></I>. (A) Each issuer free writing prospectus does not include any information that conflicts with the information
contained in the Registration Statement, any Preliminary Prospectus or the Prospectus. The foregoing sentence does not apply to statements
in or omissions from any issuer free writing prospectus based upon and in conformity with written information furnished to the Company
by you or by the Underwriter through you specifically for use therein, it being understood and agreed that the only such information furnished
by the Underwriter consists of the information described as such in Section 6(e).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(B) (1)
At the earliest time after the filing of the Registration Statement that the Company or another offering participant made a <I>bona fide
</I>offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Securities and (2) at the date hereof, the Company was
not and is not an &ldquo;ineligible issuer,&rdquo; as defined in Rule 405 under the Securities Act, including the Company in the preceding
three years not having been convicted of a felony or misdemeanor or having been made the subject of a judicial or administrative decree
or order as described in Rule 405 of the Rules and Regulations (without taking account of any determination by the Commission pursuant
to Rule 405 of the Rules and Regulations that it is not necessary that the Company be considered an ineligible issuer), nor an &ldquo;excluded
issuer&rdquo; as defined in Rule 164 under the Securities Act.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(C) Each
issuer free writing prospectus satisfied, as of its issue date and at all subsequent times to the Time of Sale, all other conditions to
use thereof as set forth in Rules 164 and 433 under the Securities Act.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iv) <I><U>No
Other Offering Materials</U></I>. The Company has not distributed and will not distribute any prospectus or other offering material in
connection with the offering and sale of the Securities other than any Preliminary Prospectus, the Time of Sale Disclosure Package or
the Prospectus or other materials permitted by the Act to be distributed by the Company; <I>provided, however,</I> that, except as set
forth on Schedule I, the Company has not made and will not make any offer relating to the Securities that would constitute a free writing
prospectus, except in accordance with the provisions of Section 4(a)(xv) of this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(v) <I><U>Financial
Statements</U></I>. The financial statements of the Company, together with the related notes, set forth or incorporated by reference in
the Registration Statement, the Time of Sale Disclosure Package and the Prospectus comply in all material respects with the requirements
of the Securities Act and the Exchange Act and fairly present the financial condition of the Company as of the dates indicated and the
results of operations and changes in cash flows for the periods therein specified in conformity with generally accepted accounting principles
in the United States consistently applied throughout the periods involved; the supporting schedules included in the Registration Statement
fairly present the information required to be stated
therein; all non-GAAP financial information included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus
complies in all material respects with the requirements of Regulation G and Item 10 of Regulation S-K under the Act; and, except as disclosed
in the Time of Sale Disclosure Package and the Prospectus, there are no material off-balance sheet arrangements (as defined in Regulation
S-K under the Act, Item 303(a)(4)(ii)) or any other relationships with unconsolidated entities or other persons, that may have a material
current or, to the Company&rsquo;s knowledge, material future effect on the Company&rsquo;s financial condition, results of operations,
liquidity, capital expenditures, capital resources or significant components of revenue or expenses. No other financial statements or
schedules are required to be included in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus. To the Company&rsquo;s
knowledge, Baker Tilly US LLP, which has expressed its opinion with respect to the audited financial statements and schedules, if any,
filed as a part of the Registration Statement and included in the Registration Statement, the Time of Sale Disclosure Package and the
Prospectus, is (x) an independent public accounting firm within the meaning of the Act and the Rules and Regulations, (y) a registered
public accounting firm (as defined in Section 2(a)(12) of the Sarbanes-Oxley Act of 2002 (the <B><I>&ldquo;Sarbanes-Oxley Act&rdquo;</I></B>))
and (z) not in violation of the auditor independence requirements of the Sarbanes-Oxley Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(vi) <I><U>Organization
and Good Standing</U></I>. The Company has been duly organized and is validly existing as a corporation in good standing under the laws
of its jurisdiction of incorporation. The Company has full corporate power and authority to own its properties and conduct its business
as currently being carried on and as described in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus,
and is duly qualified to do business as a foreign corporation in good standing in each jurisdiction in which it owns or leases real property
or in which the conduct of its business makes such qualification necessary and in which the failure to so qualify would have a material
adverse effect upon the business, prospects, management, properties, operations, condition (financial or otherwise), financial position
or results of operations of the Company, taken as a whole (<B><I>&ldquo;Material Adverse Effect&rdquo;</I></B>).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(vii) <I><U>Absence
of Certain Events</U></I>. Except as contemplated in the Time of Sale Disclosure Package and in the Prospectus, subsequent to the respective
dates as of which information is given in the Time of Sale Disclosure Package and the Prospectus, the Company has not incurred any material
liabilities or obligations, direct or contingent, or entered into any material transactions, or declared or paid any dividends or made
any distribution of any kind with respect to its capital stock; and there has not been any change in the capital stock (other than a change
in the number of outstanding shares of Common Stock due to the issuance of shares upon the exercise or settlement of outstanding options,
restricted share units or warrants or conversion of convertible securities or due to the cancellation or redemption of shares under existing
equity incentive plans), or any material change in the short-term or long-term debt (other than as a result of the conversion of convertible
securities), or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock of the Company,
or any material adverse change in the general affairs, condition (financial or otherwise), business, prospects, management, properties,
operations, financial position or results of operations of the Company (<B><I>&ldquo;Material Adverse Change&rdquo;</I></B>)
or any development which could reasonably be expected to result in any Material Adverse Change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(viii) <I><U>Absence
of Proceedings</U></I>. Except as set forth in the Time of Sale Disclosure Package and in the Prospectus, there is not pending or, to
the knowledge of the Company, threatened or contemplated, any action, suit or proceeding (a) to which the Company is a party or (b) which
has as the subject thereof any officer or director of the Company, any employee benefit plan sponsored by the Company or any property
or assets owned or leased by the Company before or by any court or Governmental Authority (as defined below), or any arbitrator, which,
individually or in the aggregate, would result in a Material Adverse Effect. There are no current or, to the knowledge of the Company,
pending, legal, governmental or regulatory actions, suits or proceedings (x) to which the Company is subject or (y) which has as the subject
thereof any officer or director of the Company, any employee plan sponsored by the Company or any property or assets owned or leased by
the Company, that are required to be described in the Registration Statement, Time of Sale Disclosure Package and Prospectus by the Act
or by the Rules and Regulations and that have not been so described.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ix) <I><U>Disclosure
of Legal Matters</U></I>. There are no statutes, regulations, contracts or documents that are required to be described in the Registration
Statement, in the Time of Sale Disclosure Package and in the Prospectus or required to be filed as exhibits to the Registration Statement
by the Securities Act or by the Rules and Regulations that have not been so described or filed.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(x) <I><U>Authorization;
No Conflicts; Authority</U></I>. This Agreement has been duly authorized, executed and delivered by the Company, and constitutes a valid,
legal and binding obligation of the Company, enforceable in accordance with its terms, except as rights to indemnity hereunder may be
limited by federal or state securities laws and except as such enforceability may be limited by bankruptcy, insolvency, reorganization
or similar laws affecting the rights of creditors generally and subject to general principles of equity. The execution, delivery and performance
of this Agreement and the consummation of the transactions herein contemplated will not (A) conflict with or result in a breach or violation
of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition of any lien, charge or encumbrance
upon any property or assets of the Company pursuant to any indenture, mortgage, deed of trust, loan agreement or other material agreement
or instrument to which the Company is a party or by which the Company is bound or to which any of the property or assets of the Company
is subject, (B) result in any violation of the provisions of the Company&rsquo;s charter or by-laws or (C) result in the violation of
any law or statute or any judgment, order, rule, regulation or decree of any court or arbitrator or federal, state, local or foreign governmental
agency or regulatory authority having jurisdiction over the Company or any of its properties or assets (each, a <B><I>&ldquo;Governmental
Authority&rdquo;</I></B>), except in the case of clauses (A) and (C) as would not result in a Material Adverse Effect. No consent, approval,
authorization or order of, or registration or filing with any Governmental Authority is required for the execution, delivery and performance
of this Agreement or for the consummation of the transactions contemplated hereby, including the issuance or sale of the Securities by
the Company, except such as may be required under the Act, the rules of the Financial Industry Regulatory Authority (<B><I>&ldquo;FINRA&rdquo;</I></B>),
the Nasdaq Stock Market Rules or state securities or blue sky laws; and the Company has full power and authority to enter into this Agreement
and to consummate the transactions contemplated hereby, including the authorization, issuance and sale of the Securities as contemplated
by this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xi) <I><U>Capitalization;
the Securities; Registration Rights</U></I>. All of the issued and outstanding shares of capital stock of the Company are duly
authorized and validly issued, fully paid and nonassessable, have been issued in compliance with all federal and state and foreign
securities laws, were not issued in violation of or subject to any preemptive rights or other rights to subscribe for or purchase
securities that have not been waived in writing (a copy of which has been delivered to counsel to the Underwriter), and the holders
thereof are not subject to personal liability by reason of being such holders; the Securities which may be sold hereunder by the
Company have been duly authorized and, when issued, delivered and paid for in accordance with the terms of this Agreement, will have
been validly issued and will be fully paid and nonassessable, and the holders thereof will not be subject to personal liability by
reason of being such holders; and the capital stock of the Company, including the Common Stock and the Securities to be purchased
pursuant to this Agreement, conforms to the description thereof in the Registration Statement, in the Time of Sale Disclosure
Package and in the Prospectus. Except as otherwise stated in the Registration Statement, in the Time of Sale Disclosure Package and
in the Prospectus, (A) there are no preemptive rights or other rights to subscribe for or to purchase, or any restriction upon the
voting or transfer of, any shares of Common Stock pursuant to the Company&rsquo;s charter, by-laws or any agreement or other
instrument to which the Company is a party or by which the Company is bound; (B) neither the filing of the Registration Statement
nor the offering or sale of the Securities as contemplated by this Agreement gives rise to any rights for or relating to the
registration of any shares of Common Stock or other securities of the Company (collectively <B><I>&ldquo;Registration
Rights&rdquo;</I></B>) and (C) any person to whom the Company has granted Registration Rights has agreed not to exercise such rights
until after expiration of the Lock-Up Period (as defined below). The Company has an authorized and outstanding capitalization as set
forth in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xii) <I><U>Stock
Options</U></I>. Except as described in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus, there
are no options, warrants, agreements, contracts or other rights in existence to purchase or acquire from the Company any shares of the
capital stock of the Company. The description of the Company&rsquo;s stock option, stock bonus and other stock plans or arrangements (the
<B><I>&ldquo;Company Stock Plans&rdquo;</I></B>), and the options or other rights granted thereunder (collectively, the <B><I>&ldquo;Awards&rdquo;</I></B>),
set forth in the Time of Sale Disclosure Package and the Prospectus presents accurately and fairly in all material respects the information
required to be shown with respect to such plans, arrangements and Awards. Each grant of an Award (A) was duly authorized no later than
the date on which the grant of such Award was by its terms to be effective by all necessary corporate action, including, as applicable,
approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder
approval by the necessary number of votes or written consents, and the award agreement governing such grant (if any) was duly executed
and delivered by each party thereto and (B) was made in accordance with the terms of the applicable Company Stock Plan, and all applicable laws and regulatory rules or requirements,
including all applicable federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xiii) <I><U>Compliance
with Laws</U></I>. The Company is operating in compliance in all material respects with, all franchises, grants, authorizations, licenses,
permits, easements, consents, certificates and orders of any Governmental Authority or self-regulatory body required for the conduct of
its business and all such material franchises, grants, authorizations, licenses, permits, easements, consents, certifications and orders
are valid and in full force and effect; and the Company has not received written notice of any revocation or modification of any material
franchise, grant, authorization, license, permit, easement, consent, certification or order or has reason to believe that any such material
franchise, grant, authorization, license, permit, easement, consent, certification or order will not be renewed in the ordinary course;
and the Company is in compliance in all material respects with all applicable federal, state, local and foreign laws, regulations, orders
and decrees.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xiv) <I><U>Ownership
of Assets</U></I>. The Company has good and marketable title to, or has valid rights to lease or otherwise use, all property (whether
real or personal) described in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus as being owned,
leased or used by them, in each case free and clear of all material liens, claims, security interests, other encumbrances or defects except
such as are described in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus and except as would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. The property held under lease by the
Company is held by it under valid, subsisting and enforceable leases with only such exceptions with respect to any particular lease as
do not interfere in any material respect with the conduct of the business of the Company.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"> (xv) <I><U>Intellectual Property</U></I>.</P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(A) The
Company owns or has the right to use pursuant to a valid and enforceable written license or other legally enforceable right, all Intellectual
Property (as defined below) necessary for the conduct of the Company&rsquo;s business as now conducted or as described in the Registration
Statement, the Time of Sale Disclosure Package and the Prospectus to be conducted (the <B><I>&ldquo;Company IP&rdquo;</I></B>), except
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. <B><I>&ldquo;Intellectual Property&rdquo;
</I></B>means all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights,
licenses, inventions, trade secrets, domain names, technology, know-how and other intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(B) To
the knowledge of the Company, there is no infringement, misappropriation or violation by third parties of any Company IP, except for such
infringement, misappropriation or violation that would not reasonably be expected to have a Material Adverse Effect. There is no pending
or, to the knowledge of the Company, threatened, action, suit, proceeding or claim by others challenging the Company&rsquo;s rights in
or to any Company IP, and the Company is unaware of any facts which would form a reasonable basis for
any such claim, except where such action, suit, proceeding or claim would not reasonably be expected to have a Material Adverse Effect.
The Intellectual Property owned by the Company, and to the knowledge of the Company, the Intellectual Property licensed to the Company,
has not been adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened
action, suit, proceeding or claim by others challenging the validity or scope of any Company IP, and the Company is unaware of any facts
which would form a reasonable basis for any such claim. There is no pending or, to the knowledge of the Company, threatened action, suit,
proceeding or claim by others that the Company infringes, misappropriates or otherwise violates any Intellectual Property or other proprietary
rights of others, and the Company has not received any written notice of such claim and the Company is unaware of any other fact which
would form a reasonable basis for any such claim, except where such action, suit, proceeding or claim would not reasonably be expected
to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(C) To
the Company&rsquo;s knowledge, no employee of the Company is in or has ever been in material violation of any term of any employment contract,
patent disclosure agreement, invention assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement
or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&rsquo;s employment
with the Company or actions undertaken by the employee while employed with the Company.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(D) The
Company has taken commercially reasonable security measures to protect the secrecy, confidentiality and value of all of its material Intellectual
Property.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(E) All
patent applications owned by the Company and filed with the U.S. Patent and Trademark Office (the <B><I>&ldquo;PTO&rdquo;</I></B>) or
any foreign or international patent authority that have resulted in patents or currently pending applications that describe inventions
necessary to conduct the business of the Company as now conducted or as described in the Registration Statement, the Time of Sale Disclosure
Package and the Prospectus to be conducted (collectively, the <B><I>&ldquo;Company Patent Applications&rdquo;</I></B>) have been or were
duly and properly filed.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(F) The
Company has complied with its duty of candor and disclosure to the PTO for the Company Patent Applications. To the Company&rsquo;s knowledge,
there are no facts required to be disclosed to the PTO that were not disclosed to the PTO and which would preclude the grant of a patent
for the Company Patent Applications. The Company has no knowledge of any facts which would preclude it from having clear title to the
Company Patent Applications that have been identified by the Company as being exclusively owned by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(xvi) <I><U>Privacy and Data Protection</U></I>. The
Company has operated its business in a manner compliant in all material respects with all United States federal, state, local and non-United States privacy, data security
and data protection laws and regulations applicable to the Company&rsquo;s collection, use, transfer, protection, disposal, disclosure,
handling, storage and analysis of personal data. The Company has been and is in compliance in all material respects with internal policies
and procedures designed to ensure the integrity and security of the data collected, handled or stored in connection with its business.
The Company has taken commercially reasonable steps to maintain the confidentiality of its personally identifiable information, protected
health information, consumer information and other confidential information of the Company and any third parties in its possession (&ldquo;<B><I>Sensitive
Company Data</I></B>&rdquo;). The tangible or digital information technology systems (including computers, screens, servers, workstations,
routers, hubs, switches, networks, data communications lines, technical data and hardware), software and telecommunications systems used
or held for use by the Company (the &ldquo;<B><I>Company IT Assets</I></B>&rdquo;) are in all material respects adequate and operational
for, in accordance with its documentation and functional specifications, the business of the Company as now operated and as currently
proposed to be conducted as described in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus. The
Company has used commercially reasonable efforts to establish, and has established, commercially reasonable disaster recovery and security
plans, procedures and facilities for the business consistent with industry standards and practices in all material respects, including,
without limitation, for the Company IT Assets and data held or used by or for the Company. To the Company&rsquo;s knowledge, the Company
has not suffered or incurred any security breaches, compromises or incidents with respect to any Company IT Asset or Sensitive Company
Data, except where such breaches, compromises or incidents would not reasonably be expected to, singly or in the aggregate, result in
a Material Adverse Effect; and there has been no unauthorized or illegal use of or access to any Company IT Asset or Sensitive Company
Data by any unauthorized third party, except where such unauthorized or illegal use or access would not reasonably be expected to, individually
or in the aggregate, have a Material Adverse Effect. The Company has not been required to notify any individual of any information security
breach, compromise or incident involving Sensitive Company Data.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xvii) <I><U>No
Violations or Defaults</U></I>. The Company is not (i) in violation of its respective charter, by-laws or other organizational documents,
or (ii) in breach of or otherwise in default, and no event has occurred which, with notice or lapse of time or both, would constitute
such a default in the performance of any obligation, agreement or condition contained in any bond, debenture, note, indenture, loan agreement
or any other contract, lease or other instrument to which it is subject or by which any of them may be bound, or to which any of the property
or assets of the Company is subject, except, in the case of clause (ii), as would not have a Material Adverse Effect.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xviii) <I><U>Taxes</U></I>.
The Company has timely filed all federal, state, local and foreign income and franchise tax returns required to be filed (except where
the failure to make such timely filing would not be material) and is not in material default in the payment of any taxes which were payable
pursuant to said returns or any assessments with respect thereto, other than any which the Company is contesting in good faith. There
is no pending dispute with any taxing authority relating to any of such returns, and the Company has no knowledge of any proposed liability for any tax to be imposed
upon the properties or assets of the Company for which there is not an adequate reserve reflected in the Company&rsquo;s financial statements
included in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xix) <I><U>Exchange
Listing and Exchange Act Registration</U></I>. The Common Stock is registered pursuant to Section 12(b) of the Exchange Act and is included
or approved for listing on the Nasdaq Capital Market and the Company has not taken any action designed to, or likely to have the effect
of, terminating the registration of the Common Stock under the Exchange Act or delisting the Common Stock from the Nasdaq Capital Market,
and the Company has not received any notification that the Commission or the Nasdaq Capital Market is contemplating terminating such registration
or listing. The Company has complied in all material respects with the applicable requirements of the Nasdaq Capital Market for maintenance
of inclusion of the Common Stock thereon. Except as previously disclosed to counsel for the Underwriter or as set forth in the Time of
Sale Disclosure Package and the Prospectus, to the knowledge of the Company, no beneficial owners of the Company&rsquo;s capital stock
who, together with their associated persons and affiliates, hold in the aggregate 10% or more of such capital stock, have any direct or
indirect association or affiliate with a FINRA member.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xx) <I><U>Ownership
of Other Entities</U></I>. The Company, directly or indirectly, owns no capital stock or other equity or ownership or proprietary interest
in any corporation, partnership, association, trust or other entity.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxi) <I><U>Internal
Controls</U></I>. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurances that (i)
transactions are executed in accordance with management&rsquo;s general or specific authorization; (ii) transactions are recorded as necessary
to permit preparation of financial statements in conformity with generally accepted accounting principles in the United States and to
maintain accountability for assets; (iii) access to assets is permitted only in accordance with management&rsquo;s general or specific
authorization; and (iv) the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate
action is taken with respect to any differences. Except as disclosed in the Registration Statement, in the Time of Sale Disclosure Package
and in the Prospectus, the Company&rsquo;s internal control over financial reporting is effective and none of the Company, its board of
directors and audit committee is aware of any &ldquo;significant deficiencies&rdquo; or &ldquo;material weaknesses&rdquo; (each as defined
by the Public Company Accounting Oversight Board) in its internal control over financial reporting, or any fraud, whether or not material,
that involves management or other employees of the Company who have a significant role in the Company&rsquo;s internal controls; and since
the end of the latest audited fiscal year, there has been no change in the Company&rsquo;s internal control over financial reporting (whether
or not remediated) that has materially affected, or is reasonably likely to materially affect, the Company&rsquo;s internal control over
financial reporting. The Company&rsquo;s board of directors has, subject to the exceptions, cure periods and the phase in periods specified
in the applicable stock exchange rules (<B><I>&ldquo;Exchange Rules&rdquo;</I></B>), validly appointed an audit committee to oversee internal
accounting controls whose composition satisfies the applicable requirements of the Exchange Rules and the Company&rsquo;s board of directors
and/or the audit committee has adopted a charter that satisfies the requirements
of the Exchange Rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxii) <I><U>No
Brokers or Finders</U></I>. Other than as contemplated by this Agreement, the Company has not incurred any liability for any finder&rsquo;s
or broker&rsquo;s fee or agent&rsquo;s commission in connection with the execution and delivery of this Agreement or the consummation
of the transactions contemplated hereby.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxiii) <I><U>Insurance</U></I>.
The Company carries, or is covered by, insurance from reputable insurers in such amounts and covering such risks as the Company reasonably
believes is adequate for the conduct of its business and the value of its properties and as is customary for companies engaged in similar
businesses in similar industries; all policies of insurance and any fidelity or surety bonds insuring the Company or its business, assets,
employees, officers and directors are in full force and effect; the Company is in compliance with the terms of such policies and instruments
in all material respects; there are no claims by the Company under any such policy or instrument as to which any insurance company is
denying liability or defending under a reservation of rights clause; the Company has not been refused any insurance coverage sought or
applied for; and the Company has no reason to believe that it will not be able to renew its existing insurance coverage as and when such
coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue its business at a cost that would
not have a Material Adverse Effect.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxiv) <I><U>Investment
Company Act</U></I>. The Company is not and, after giving effect to the offering and sale of the Securities, will not be an &ldquo;investment
company,&rdquo; as such term is defined in the Investment Company Act of 1940, as amended.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxv) <I><U>Eligibility
to Use Form S-3</U></I>. The conditions for use of Form S-3, in connection with the offer and sale of the Securities, as set forth in
the General Instructions thereto, have been satisfied.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxvi) <I><U>Incorporated
Documents</U></I>. The documents incorporated by reference in the Time of Sale Disclosure Package and in the Prospectus, when they became
effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Securities
Act or the Exchange Act, as applicable, and were filed on a timely basis with the Commission and none of such documents contained an untrue
statement of a material fact or omitted to state a material fact necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading; any further documents so filed and incorporated by reference in the Time of Sale Disclosure
Package or in the Prospectus, when such documents are filed with the Commission, will conform in all material respects to the requirements
of the Exchange Act, and will not contain an untrue statement of a material fact or omit to state a material fact necessary to make the
statements therein, in light of the circumstances under which they were made, not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxvii) <I><U>Sarbanes-Oxley
Act</U></I>. The Company is in compliance in all material respects with all applicable provisions of the Sarbanes-Oxley Act and the rules
and regulations of the Commission thereunder.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxviii) <I><U>Disclosure
Controls</U></I>. The Company has established and maintains disclosure controls and procedures (as defined in Rules 13a-14 and 15d-14
under the Exchange Act) and such controls and procedures are effective in ensuring that material information relating to the Company is
made known to the principal executive officer and the principal financial officer. The Company has utilized such controls and procedures
in preparing and evaluating the disclosures in the Registration Statement, in the Time of Sale Disclosure Package and in the Prospectus.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxix) <I><U>Anti-Bribery
and Anti-Money Laundering Laws</U></I>. Each of the Company, and, to the knowledge of the Company, its affiliates and any of their respective
officers, directors, supervisors, managers, agents or employees, has not violated, its participation in the offering will not violate,
and the Company has instituted and maintains policies and procedures designed to ensure continued compliance with, each of the following
laws: anti-bribery laws, including but not limited to, any applicable law, rule, or regulation of any locality, including but not limited
to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, signed December 17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery
Act 2010, or any other law, rule or regulation of similar purposes and scope, or anti-money laundering laws, including but not limited
to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering,
including, without limitation, Title 18 U.S. Code Section 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money
laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering,
of which the United States is a member and with which designation the United States representative to the group or organization continues
to concur, all as amended, and any executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any
orders or licenses issued thereunder.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in"> (xxx) <I><U>OFAC</U></I>.</P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(A) The
Company is not, and none of its directors, officers or employees, nor, to the Company&rsquo;s knowledge, any agent, affiliate or representative
of the Company, is an individual or entity that is, or is owned or controlled by an individual or entity that is:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 1in">(1) the
subject of any sanctions administered or enforced by the U.S. Department of Treasury&rsquo;s Office of Foreign Assets Control, the United
Nations Security Council, the European Union, His Majesty&rsquo;s Treasury, or other relevant sanctions authority (collectively, <B><I>&ldquo;Sanctions&rdquo;</I></B>),
nor</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 1in">(2) located,
organized or resident in a country or territory that is the subject of Sanctions (including, without limitation, the Crimea Region of
Ukraine, the so-called Donetsk People&rsquo;s Republic, the so-called Luhansk People&rsquo;s Republic and the non-government controlled
areas of the Zaporizhzhia and Kherson Regions, Cuba, Iran, North Korea and Syria).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(B) The
Company will not, directly or indirectly, use the proceeds of the offering, or lend, contribute or otherwise make available such proceeds
to any joint venture partner or other individual or entity:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 1in">(1) to
fund or facilitate any activities or business of or with any individual or entity or in any country or territory that, at the time of
such funding or facilitation, is the subject of Sanctions; or</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: left; text-indent: 1in">(2) in
any other manner that will result in a violation of Sanctions by any individual or entity (including any individual or entity participating
in the offering, whether as underwriter, advisor, investor or otherwise).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(C) For
the past five years, the Company has not knowingly engaged in, and is not now knowingly engaged in, any dealings or transactions with
any individual or entity, or in any country or territory, that at the time of the dealing or transaction is or was the subject of Sanctions.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxi) <I><U>Compliance
with Environmental Laws</U></I>. Except as disclosed in the Time of Sale Disclosure Package and the Prospectus, the Company is not in
violation of any statute, any rule, regulation, decision or order of any Governmental Authority or any court, domestic or foreign, relating
to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human
exposure to hazardous or toxic substances (collectively, <B><I>&ldquo;Environmental Laws&rdquo;</I></B>), owns or operates any real property
contaminated with any substance that is subject to any Environmental Laws, is liable for any off-site disposal or contamination pursuant
to any Environmental Laws, or is subject to any claim relating to any Environmental Laws, which violation, contamination, liability or
claim would, individually or in the aggregate, have a Material Adverse Effect; and the Company has no knowledge of any pending investigation
which might lead to such a claim nor is the Company anticipating incurring any material capital expenditures relating to compliance with
Environmental Laws.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxii) <I><U>Compliance
with Occupational Laws</U></I>. The Company (A) is in compliance, in all material respects, with any and all applicable foreign,
federal, state and local laws, rules, regulations, treaties, statutes and codes promulgated by any and all Governmental Authorities
(including pursuant to the Occupational Health and Safety Act) relating to the protection of human health and safety in the
workplace (<B><I>&ldquo;Occupational Laws&rdquo;</I></B>); (B) has received all material permits, licenses or other approvals
required of it under applicable Occupational Laws to conduct its business as currently conducted; and (C) is in compliance, in all
material respects, with all terms and conditions of such permit, license or approval. No action, proceeding, revocation
proceeding, writ, injunction or claim is pending or, to the Company&rsquo;s knowledge, threatened against the Company relating to Occupational
Laws, and the Company does not have knowledge of any facts, circumstances or developments relating to its operations or cost accounting
practices that could reasonably be expected to form the basis for or give rise to such actions, suits, investigations or proceedings,
except where such action, suit, investigation or proceeding would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxiii) <I><U>ERISA
and Employee Benefits Matters</U></I>. (A) To the knowledge of the Company, no &ldquo;prohibited transaction&rdquo; as defined under Section
406 of ERISA or Section 4975 of the Code and not exempt under ERISA Section 408 and the regulations and published interpretations by the
United States Department of Labor thereunder has occurred with respect to any Employee Benefit Plan. At no time has the Company or any
ERISA Affiliate, maintained, sponsored, participated in, contributed to or has or had any liability or obligation in respect of any Employee
Benefit Plan subject to Part 3 of Subtitle B of Title I of ERISA, Title IV of ERISA, or Section 412 of the Code or any &ldquo;multiemployer
plan&rdquo; as defined in Section 3(37) of ERISA or any multiple employer plan for which the Company or any ERISA Affiliate has incurred
or could incur liability under Section 4063 or 4064 of ERISA. No Employee Benefit Plan provides or promises, or at any time provided or
promised, retiree health, life insurance, or other retiree welfare benefits except as may be required by the Consolidated Omnibus Budget
Reconciliation Act of 1985, as amended, or similar state law. Each Employee Benefit Plan is and has been operated in material compliance
with its terms and all applicable laws, including but not limited to ERISA and the Code and, to the knowledge of the Company, no event
has occurred (including a &ldquo;reportable event&rdquo; as such term is defined in Section 4043 of ERISA) and no condition exists that
would subject the Company or any ERISA Affiliate to any material tax, fine, lien, penalty or liability imposed by ERISA, the Code or other
applicable law. Each Employee Benefit Plan intended to be qualified under Code Section 401(a) is so qualified and has a favorable determination
or opinion letter from the IRS upon which it can rely, and any such determination or opinion letter remains in effect and has not been
revoked; to the knowledge of the Company, nothing has occurred since the date of any such determination or opinion letter that is reasonably
likely to adversely affect such qualification; (B) with respect to each Foreign Benefit Plan, such Foreign Benefit Plan (1) if intended
to qualify for special tax treatment, meets, in all material respects, the requirements for such treatment, and (2) if required to be
funded, is funded to the extent required by applicable law, and with respect to all other Foreign Benefit Plans, adequate reserves therefor
have been established on the accounting statements of the Company; (C) the Company has no obligations under any collective bargaining
agreement with any union and no organization efforts are underway with respect to employees of the Company. As used in this Agreement,
<B><I>&ldquo;Code&rdquo; </I></B>means the Internal Revenue Code of 1986, as amended; <B><I>&ldquo;Employee Benefit Plan&rdquo; </I></B>means
any &ldquo;employee benefit plan&rdquo; within the meaning of Section 3(3) of ERISA, including, without limitation, all stock purchase,
stock option, stock-based severance, employment, change-in-control, medical, disability, fringe benefit, bonus, incentive, deferred compensation,
employee loan and all other employee benefit plans, agreements, programs, policies or other arrangements, whether or not subject to ERISA,
under which (1) any current or former employee, director or independent contractor of the Company has any present or future
right to benefits and which are contributed to, sponsored by or maintained by the Company or (2) the Company has had or has any present
or future obligation or liability; <B><I>&ldquo;ERISA&rdquo;</I></B> means the Employee Retirement Income Security Act of 1974, as amended;
<B><I>&ldquo;ERISA Affiliate&rdquo; </I></B>means any member of the Company&rsquo;s controlled group as defined in Code Section 414(b),
(c), (m) or (o); and <B><I>&ldquo;Foreign Benefit Plan&rdquo;</I></B> means any Employee Benefit Plan established, maintained or contributed
to outside of the United States of America or which covers any employee working or residing outside of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxiv) <I><U>Business
Arrangements</U></I>. Except in the ordinary course of the Company&rsquo;s business or as disclosed in the Registration Statement, the
Time of Sale Disclosure Package and the Prospectus, the Company has not granted exclusive rights to develop, manufacture, produce, assemble,
distribute, license, market or sell its technology platform or products to any other person or is bound by any agreement that affects
the exclusive right of the Company to develop, manufacture, produce, assemble, distribute, license, market or sell its technology platform
or products.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxv) <I><U>Labor
Matters</U></I>. No labor problem or dispute with the employees of the Company exists or, to the knowledge of the Company, is threatened
or imminent, and the Company has no knowledge of any existing or imminent labor disturbance by the employees of any of its principal suppliers,
contractors or customers, that could have a Material Adverse Effect.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxvi) <I><U>Statistical
Information</U></I>. Any third-party statistical and market- related data included in the Registration Statement, the Time of Sale Disclosure
Package and the Prospectus are based on or derived from sources that the Company believes to be reasonably current and reliable and accurate
in all material respects.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxvii) <I><U>Forward-looking
Statements</U></I>. No forward-looking statement (within the meaning of Section 27A of the Act and Section 21E of the Exchange Act) contained
in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus has been made or reaffirmed without a reasonable
basis or has been disclosed other than in good faith.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxviii)
<I><U>Preclinical and Clinical Studies, Tests and Trials</U></I>. Except as described in each of the Time of Sale Disclosure Package and
the Prospectus and except as it would not, individually or in the aggregate, have a Material Adverse Effect, (i) any preclinical or clinical
studies, tests and trials conducted by or, to the knowledge of the Company, on behalf of or sponsored by the Company or in which the Company
has participated, that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, or the results
of which are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, as applicable, were, and if
still pending are, being conducted in accordance with their respective protocols, the applicable rules and regulations of the U.S. Food
and Drug Administration (the &ldquo;<B><I>FDA</I></B>&rdquo;), including, without limitation, any foreign, federal, state or local governmental
or regulatory authority performing functions similar to those performed by the FDA (collectively, the &ldquo;<B><I>Regulatory Authorities</I></B>&rdquo;),
and current applicable Good Clinical Practices and Good Laboratory Practices; (ii) the descriptions in the Registration Statement, the
Pricing Disclosure Package and the Prospectus of the results of such preclinical or clinical studies, tests and trials are accurate and
fairly present the data derived therefrom; (iii) the Company has no knowledge of any other preclinical or clinical studies, tests or trials
not described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the results of which, considered together
with the results of the Company&rsquo;s preclinical or clinical studies, tests and trials received to date, call into question the results
described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (iv) the Company has operated
at all times and are currently in compliance with all applicable statutes, rules and regulations of the Regulatory Authorities; and (v)
the Company has not received any written notices, correspondence or other communications from the Regulatory Authorities or any other
governmental agency requiring or threatening the termination, modification or suspension of any preclinical or clinical studies, tests
or trials that are described in the Registration Statement, the Pricing Disclosure Package and the Prospectus or the results of which
are referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus, other than ordinary course communications
with respect to modifications in connection with the design and implementation of such preclinical or clinical studies, tests or trials,
and, to the Company&rsquo;s knowledge, there are no reasonable grounds for the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xxxix) <I><U>Regulatory
Filings</U></I>. Except as described in each of the Time of Sale Disclosure Package and the Prospectus and except as it would not, individually
or in the aggregate, have a Material Adverse Effect, (i) the Company has not failed to file, obtain, maintain, or submit with the Regulatory
Authorities any required documents, forms, notices, applications, records, claims, filings, declarations, listings, registrations, reports,
submissions, supplements or amendments that are a responsibility with the Company with respect to the Company&rsquo;s product candidates
that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus; (ii) all such documents,
forms, notices, applications, records, claims, filings, declarations, listings, registrations, reports, submissions, supplements or amendments
were to the Company&rsquo;s knowledge timely, complete, accurate, not misleading and otherwise in compliance with applicable laws when
filed (or were corrected or supplemented by a subsequent submission); and (iii) to the Company&rsquo;s knowledge no deficiencies regarding
compliance with applicable law have been asserted by any applicable Regulatory Authority with respect to any such documents, forms, notices,
applications, records, claims, filings, declarations, listings, registrations, reports, submissions, supplements or amendments.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(xl) <I><U>Regulatory
Matters</U></I>. Except as described in each of the Time of Sale Disclosure Package and the Prospectus and except as it would not,
individually or in the aggregate, have a Material Adverse Effect, the Company is, and at all times has been, in compliance with all
applicable Health Care Laws. For purposes of this Agreement, &ldquo;<B><I>Health Care Laws</I></B>&rdquo; means: (i) the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. &sect;&sect; 301 et seq.), the Public Health Service Act (42 U.S.C. &sect;&sect; 201 et
seq.); (ii) all applicable federal, state, local and all applicable foreign health care related fraud and abuse laws, including,
without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. &sect; 1320a-7b(b)), the U.S. False Statements Law (42 U.S.C. &sect;
1320a-7b(a)), the Civil Monetary Penalties Law (42 U.S.C. &sect;1320a-7a), the U.S. Civil False Claims Act (31 U.S.C. &sect; 3729 et
seq.), all criminal laws relating to health care fraud and abuse, including but not limited to 18 U.S.C. &sect;&sect; 286 and 287,
and the health care fraud criminal provisions under the U.S. Health Insurance Portability and Accountability Act of 1996
(&ldquo;<B><I>HIPAA</I></B>&rdquo;) (42 U.S.C. &sect;&sect; 1320d et seq.), the exclusion law (42 U.S.C. &sect;1320a-7); (iii)
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C. &sect;&sect; 17921 et seq.);
(iv) regulations promulgated pursuant to such statutes; and (v) any and all other applicable federal, state, or foreign health care
laws and regulation applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured
or distributed by the Company. The Company has not received written notice of any claim, action, suit, proceeding, hearing,
enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or
third party alleging that it is in violation of any Health Care Laws, and, to the Company&rsquo;s knowledge, no such claim, action,
suit, proceeding, hearing, enforcement, investigation, arbitration or other action is threatened. Neither the Company, nor to the
Company&rsquo;s knowledge, its officers, directors, employees, contractors or agents, is a party to any corporate integrity
agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or
Regulatory Authority. Additionally, neither the Company nor any of its employees, officers, directors, contractors or agents, has
been excluded, suspended or debarred from participation in any U.S. federal health care program (as defined in 42 U.S.C. &sect;
1320a-7b(f)) or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation,
proceeding, or other similar action that would reasonably be expected to result in such debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) Effect
of Certificates. Any certificate signed by any officer of the Company and delivered to you or to counsel for the Underwriter shall be
deemed a representation and warranty by the Company to the Underwriter as to the matters covered thereby.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">3.
</FONT><B><I>Purchase, Sale and Delivery of Securities.</I></B></P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) <I><U>Firm
Shares</U></I>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and
conditions herein set forth, the Company agrees to sell the Firm Shares to the Underwriter, and the Underwriter agrees, severally
and not jointly, to purchase from the Company the number of Firm Shares set forth opposite the name of such Underwriter in Schedule
I hereto. The purchase price for each Firm Share shall be $0.93 per share. In making this Agreement, the Underwriter is contracting
severally and not jointly; except as provided in paragraph (b) of this Section 3, the agreement of the Underwriter is to purchase
only the respective number of Firm Shares specified in Schedule I.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">The Firm Shares will be
delivered by the Company to you for the accounts of the Underwriter against payment of the purchase price therefor by wire transfer
of same day funds payable to the order of the Company at the offices of The Benchmark Company, LLC, 150 East 58th Street, 17th Floor
New York, New York 10155, or such other location as may be mutually acceptable, at 9:00 a.m. Central time, or such other time as you
and the Company may agree upon, on the second (or if the Securities are priced, as contemplated by Rule 15c6-1(c) under the Exchange
Act, after 4:30 p.m. Eastern time, the third) full business day following the date hereof, or at such other time and date as you and
the Company determine pursuant to Rule 15c6-1(a) under the Exchange Act, such time and date of delivery being herein referred to as
the <B><I>&ldquo;First Closing Date.&rdquo;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I></I></B></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) <I><U>Option
Shares</U></I>. On the basis of the representations, warranties and agreements herein contained, but subject to the terms and conditions
herein set forth, the Company hereby grants to the Underwriter an option to purchase all or any portion of the Option Shares at the same
purchase price as the Firm Shares, for use solely in covering any over-allotments made by the Underwriter in the sale and distribution
of the Firm Shares. The option granted hereunder may be exercised in whole or in part at any time (but not more than once) within 30 days
after the effective date of this Agreement upon notice (confirmed in writing) by the Underwriter to the Company setting forth the aggregate
number of Option Shares as to which the Underwriter is exercising the option, the names and denominations in which the certificates for
the Option Shares are to be registered and the date and time, as determined by you, when the Option Shares are to be delivered, such time
and date being herein referred to as the <B><I>&ldquo;Second Closing&rdquo; </I></B>and <B><I>&ldquo;Second Closing Date,&rdquo; </I></B>respectively;
provided, however, that the Second Closing Date shall not be earlier than the First Closing Date nor earlier than the second business
day after the date on which the option shall have been exercised. Each of the First Closing Date and the Second Closing Date may be referred
to herein as a &ldquo;<B><I>Closing Date</I></B>.&rdquo; The Underwriter agrees, severally and not jointly, to purchase the number of
Option Shares (subject to such adjustments to eliminate fractional shares as you may determine) that bears the same proportion of the
total number of Option Shares to be purchased on such Second Closing Date as the number of Firm Shares set forth in Schedule I hereto
opposite the name of such Underwriter bears to the total number of Firm Shares. No Option Shares shall be sold and delivered unless the
Firm Shares previously have been, or simultaneously are, sold and delivered.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">The Option Shares will be delivered
by the Company to you for the accounts of the Underwriter against payment of the purchase price therefor by wire transfer of same day
funds payable to the order of the Company at the offices of The Benchmark Company, LLC, 150 East 58th Street, 17th Floor New York, New
York 10155, or such other location as may be mutually acceptable at 9:00 a.m. Central time, or such other time as you and the Company
may agree upon, on the Second Closing Date.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) <I><U>Delivery</U></I>.
If the Underwriter so elects, delivery of the Firm Shares or the Option Shares may be made by credit through full fast transfer to the
accounts at The Depository Trust Company designated by the Underwriter. Certificates representing the Firm Shares and the Option Shares
in definitive form and in such denominations and registered in such names as you have set forth in your notice of option exercise, or
evidence of their issuance, will be made available for checking at a reasonable time preceding the First Closing Date or the Second Closing
Date, as applicable, at the office of The Benchmark Company, LLC, 150 East 58th Street, 17th Floor New York, New York 10155, or such other
location as may be mutually acceptable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">4.
</FONT><B><I>Covenants</I><FONT STYLE="font-style: normal">.</FONT></B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(a) <I><U>Covenants
of the Company</U></I>. The Company covenants and agrees with the Underwriter as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(i) <I><U>Required
Filings</U></I>. During the period beginning on the date hereof and ending on the later of the Second Closing Date or such date, as in
the opinion of counsel for the Underwriter, the Prospectus is no longer required by law to be delivered (assuming the absence of Rule
172 under the Securities Act), in connection with sales by an Underwriter or a dealer (the <B>&ldquo;<I>Prospectus Delivery Period&rdquo;</I></B>),
prior to amending or supplementing the Registration Statement (including any Rule 462(b) Registration Statement), the Time of Sale Disclosure
Package or the Prospectus, the Company shall furnish to you for review a copy of each such proposed amendment or supplement, and the Company
shall not file any such proposed amendment or supplement to which the Underwriter or counsel to the Underwriter reasonably object. Subject
to this Section 4(a)(i), immediately following execution of this Agreement, the Company will prepare the Prospectus containing the Rule
430B Information and other selling terms of the Securities, the plan of distribution thereof and such other information as may be required
by the Securities Act or the Rules and Regulations or as the Underwriter and the Company may deem appropriate, and if requested by the
Underwriter, an issuer free writing prospectus containing the selling terms of the Securities and such other information as the Company
and the Underwriter may deem appropriate, and will file or transmit for filing with the Commission, in accordance with Rule 424(b) or
Rule 433, as the case may be, copies of the Prospectus and each issuer free writing prospectus.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(ii) <I><U>Notification of
Certain Commission Actions</U></I>. After the date of this Agreement, the Company shall promptly advise you in writing (A) of the
receipt of any comments of, or requests for additional or supplemental information from, the Commission, (B) of the time and date of
any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any Preliminary
Prospectus, the Time of Sale Disclosure Package or the Prospectus, (C) of the time and date that any post-effective amendment to the
Registration Statement becomes effective, (D) of the issuance by the Commission of any stop order suspending the effectiveness of
the Registration Statement or any post-effective amendment thereto or of any order preventing or suspending its use or the use of
any Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus or any issuer free writing prospectus, or (E) of any
proceedings to remove, suspend or terminate from listing or quotation the Common Stock from any securities exchange upon which it is
listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings for any of such
purposes. If the Commission shall enter any such stop order at any time, the Company will use commercially reasonable efforts to
obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply with the
provisions of Rules 424(b) and 430B, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any
filings made by the Company under Rule 424(b), Rule 433 or Rule 462 were received in a timely manner by the Commission (without
reliance on Rule 424(b)(8) or Rule 164(b)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(iii) <I><U>Continued
Compliance with Securities Laws</U></I>. (A) During the Prospectus Delivery Period, the Company will comply with all requirements imposed
upon it by the Securities Act, as now and hereafter amended, and by the Rules and Regulations, as from time to time in force, and by the
Exchange Act so far as necessary to permit the continuance of sales of or dealings in the Securities as contemplated by the provisions
hereof, the Time of Sale Disclosure Package and the Prospectus. If during such period any event occurs as a result of which the Prospectus
(or if the Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) would include an untrue statement
of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances then existing,
not misleading, or if during such period it is necessary or appropriate in the opinion of the Company or its counsel or the Underwriter
or counsel to the Underwriter to amend the Registration Statement or supplement the Prospectus (or, if the Prospectus is not yet available
to prospective purchasers, the Time of Sale Disclosure Package) to comply with the Securities Act or to file under the Exchange Act any
document which would be deemed to be incorporated by reference in the Prospectus (or if the Prospectus is not yet available to prospective
purchasers, the Time of Sale Disclosure Package) in order to comply with the Securities Act or the Exchange Act, the Company promptly
will (x) notify you of such untrue statement or omission, (y) amend the Registration Statement or supplement the Prospectus (or, if the
Prospectus is not yet available to prospective purchasers, the Time of Sale Disclosure Package) or file such document (at the expense
of the Company) so as to correct such statement or omission or effect such compliance, and (z) notify you when any amendment to the Registration
Statement is filed or becomes effective or when any supplement to the Prospectus (or, if the Prospectus is not yet available to prospective
purchasers, the Time of Sale Disclosure Package) is filed.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(B) If at any time following
issuance of an issuer free writing prospectus there occurred or occurs an event or development as a result of which such issuer free writing
prospectus conflicted or would conflict with the information contained in the Registration Statement, the Preliminary Prospectus or the
Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary
in order to make the statements therein, in light of the circumstances prevailing at that subsequent time, not misleading, the Company
(x) has promptly notified or promptly will notify the Underwriter of such conflict, untrue statement or omission, (y) has promptly amended
or will promptly amend or supplement, at its own expense, such issuer free writing prospectus to eliminate or correct such conflict, untrue
statement or omission, and (z) has notified or promptly will notify you when such amendment or supplement was or is filed with the Commission
where so required to be filed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(iv) <I><U>Blue
Sky Qualifications</U></I>. The Company shall take or cause to be taken all necessary action required by law to qualify the Securities
for sale under the securities laws of such jurisdictions as you reasonably designate and to continue such qualifications in effect so
long as required for the distribution of the Securities, except that the Company shall not be required in connection therewith to qualify
as a foreign corporation or to execute a general consent to service of process in any state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(v) <I><U>Provision
of Documents</U></I>. The Company will furnish, at its own expense, to the Underwriter and counsel for the Underwriter copies of the Registration
Statement, and to the Underwriter and any dealer each Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus, any
issuer free writing prospectus, and all amendments and supplements to such documents, in each case as soon as available and in such quantities
as you may from time to time reasonably request.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(vi) <I><U>Rule
158</U></I>. The Company will make generally available to its security holders as soon as practicable, but in no event later than 15 months
after the end of the Company&rsquo;s current fiscal quarter, an earnings statement (which need not be audited) covering a 12-month period
that shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(vii) <I><U>Payment
and Reimbursement of Expenses</U></I>. The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement
is terminated, will pay or cause to be paid (A) all expenses (including transfer taxes allocated to the respective transferees) incurred
by the Company in connection with the delivery to the Underwriter of the Securities, (B) all expenses and fees (including, without limitation,
fees and expenses of the Company&rsquo;s accountants and counsel) in connection with the preparation, printing, filing, delivery, and
shipping of the Registration Statement (including the financial statements therein and all amendments, schedules, and exhibits thereto),
the Securities, each Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus, any issuer free writing prospectus and
any amendment thereof or supplement thereto, and the printing, delivery, and shipping of this Agreement and other underwriting documents,
including Blue Sky Memoranda (covering the states and other applicable jurisdictions), (C) all filing fees incurred in connection with
the qualification of the Securities for offering and sale by the Underwriter or by dealers under the securities or blue sky laws of the
states and other jurisdictions which you shall designate, (D) the fees and expenses of the transfer agent or registrar, (E) the filing
fees and fees and disbursements of Underwriter&rsquo;s counsel incident to any required review and approval by FINRA of the terms of the
sale of the Securities, (F) listing fees, if any, (G) the cost and expenses of the Company relating to investor presentations or any &ldquo;roadshow&rdquo;
undertaken in connection with marketing of the Securities, including any bookbuilding or similar software, (H) fees and disbursements
of the Underwriter&rsquo;s counsel up to a maximum of $150,000, (I) all out-of-pocket expenses of the Underwriter (including, but not
limited to, the Underwriter&rsquo;s reasonable travel, database, software, commemorative mementos and lucite tombstone, printing, postage,
facsimile and telephone expenses) incurred in connection with the Underwriter&rsquo;s investigation of the Company, preparing to market
and marketing the Securities, sale of the Securities or in contemplation of performing its obligations hereunder, which amount, in addition
to the amounts reimbursed pursuant to Section 4(a)(vii)(H), shall not exceed $175,000 in the aggregate, (J) costs of background checks
purchased by the Underwriter on the Company&rsquo;s senior management, in an amount not to exceed $7,500, and (K) all other reasonable
costs and expenses of the Company incident to the performance of its obligations hereunder that are not otherwise specifically provided
for herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(viii) <I><U>Use
of Proceeds</U></I>. The Company will apply the net proceeds from the sale of the Securities to be sold by it hereunder for the purposes
set forth in the Time of Sale Disclosure Package and in the Prospectus.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(ix) <I><U>Company
Lock Up</U></I>. (A) The Company will not, without the prior written consent of the Underwriter, from the date of execution of this Agreement
and continuing to and including the date 90 days after the date of the Prospectus (the &ldquo;Lock-Up Period&rdquo;), (A) offer, pledge,
announce the intention to sell, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock
or any securities convertible into or exercisable or exchangeable for Common Stock or (B) enter into any swap or other agreement that
transfers, in whole or in part, any of the economic consequences of ownership of the Common Stock, whether any such transaction described
in clause (A) or (B) above is to be settled by delivery of Common Stock or such other securities, in cash or otherwise, except, in each
case, for (x) the sale of the Securities as contemplated by this Agreement, (y) issuances of shares of Common Stock upon the exercise
or conversion of options or other similar equity awards, warrants or convertible securities disclosed as outstanding in the Registration
Statement, the Time of Sale Disclosure Package and the Prospectus, and (z) the issuance of employee stock options or other similar equity
awards not exercisable during the Lock-Up Period pursuant to the Company&rsquo;s stock option, stock bonus and other stock plans or arrangements,
as in effect on the date hereof in the ordinary course of business consistent with past practices. The Company agrees not to accelerate
the vesting of any option or other similar equity award or warrant or the lapse of any repurchase right prior to the expiration of the
Lock-Up Period.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(x) <I><U>Stockholder
Lock-Ups</U></I>. The Company has caused to be delivered to you prior to the date of this Agreement a letter, in the form of Exhibit A
hereto (the <B><I>&ldquo;Lock- Up Agreement&rdquo;</I></B>), from each individual or entity listed on Schedule IV. The Company will enforce
the terms of each Lock-Up Agreement and issue stop-transfer instructions to the transfer agent for the Common Stock with respect to any
transaction or contemplated transaction that would constitute a breach of or default under the applicable Lock-Up Agreement.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(xi) <I><U>No
Market Stabilization or Manipulation</U></I>. The Company has not taken and will not take, directly or indirectly, any action designed
to or which might reasonably be expected to cause or result in, or which has constituted, the stabilization or manipulation of the price
of any security of the Company to facilitate the sale or resale of the Securities.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(xii) <I><U>SEC
Reports</U></I>. During the Prospectus Delivery Period, the Company will file on a timely basis with the Commission such periodic and
special reports as required by the Rules and Regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(xiii) <I><U>Internal
Controls</U></I>. During the Prospectus Delivery Period, the Company will maintain such controls and other procedures, including without
limitation those required by Sections 302 and 906 of the Sarbanes-Oxley Act and the applicable regulations thereunder, that are designed
to ensure that information required to be disclosed by the Company in the reports that it files or
submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission&rsquo;s
rules and forms, including without limitation, controls and procedures designed to ensure that information required to be disclosed by
the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&rsquo;s management,
including its principal executive officer and its principal financial officer, or persons performing similar functions, as appropriate
to allow timely decisions regarding required disclosure, to ensure that material information relating to Company is made known to them
by others within those entities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(xiv) <I><U>Sarbanes-Oxley</U></I>.
During the Prospectus Delivery Period, the Company will comply with all applicable provisions of the Sarbanes-Oxley Act.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: 1in">(xv) <I><U>Free
Writing Prospectuses</U></I>. The Company represents and agrees that, unless it obtains the prior written consent of the
Underwriter, it has not made and will not make any offer relating to the Securities that would constitute an issuer free writing
prospectus or that would otherwise constitute a free writing prospectus required to be filed with the Commission; provided that the
prior written consent of the Underwriter shall be deemed to have been given in respect of the free writing prospectuses included in
Schedule II. Any such free writing prospectus consented to by the Underwriter is hereinafter referred to as a <B><I>&ldquo;Permitted
Free Writing Prospectus.&rdquo; </I></B>The Company represents that it has treated or agrees that it will treat each Permitted Free
Writing Prospectus as an issuer free writing prospectus and has complied and will comply with the requirements of Rule 164 and Rule
433 applicable to any Permitted Free Writing Prospectus.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">5. <B><I>Conditions
of Underwriter&rsquo;s Obligations</I></B>. The obligations of the Underwriter hereunder is subject to the accuracy, as of the date hereof
and at each of the First Closing Date and the Second Closing Date (as if made at such Closing Date), of and compliance with all representations,
warranties and agreements of the Company contained herein, to the performance by the Company of its obligations hereunder and to the following
additional conditions:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) <I><U>Required
Filings; Absence of Certain Commission Actions</U></I>. If filing of the Prospectus, or any amendment or supplement thereto, or any issuer
free writing prospectus, is required under the Securities Act or the Rules and Regulations, the Company shall have filed the Prospectus
(or such amendment or supplement) or such issuer free writing prospectus with the Commission in the manner and within the time period
so required (without reliance on Rule 424(b)(8) or Rule 164(b)); the Registration Statement shall remain effective; no stop order suspending
the effectiveness of the Registration Statement or any part thereof, any Rule 462(b) Registration Statement, or any amendment thereof,
nor suspending or preventing the use of the Time of Sale Disclosure Package, the Prospectus or any issuer free writing prospectus shall
have been issued; and no proceedings for the issuance of such an order shall have been initiated or threatened; any request of the Commission
for additional information (to be included in the Registration Statement, the Time of Sale Disclosure Package, the Prospectus, any issuer
free writing prospectus or otherwise) shall have been complied with to your satisfaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) <I><U>Continued
Compliance with Securities Laws</U></I>. The Underwriter shall not advise the Company that (i) the Registration Statement or any amendment
thereof or supplement thereto contains an untrue statement of a material fact which, in your opinion, is material or omits to state a
material fact which, in your opinion, is required to be stated therein or necessary to make the statements therein not misleading, or
(ii) the Time of Sale Disclosure Package or the Prospectus, or any amendment thereof or supplement thereto, or any issuer free writing
prospectus contains an untrue statement of fact which, in your opinion, is material, or omits to state a fact which, in your opinion,
is material and is required to be stated therein, or necessary to make the statements therein, in light of the circumstances under which
they are made, not misleading.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) <I><U>Absence
of Certain Events</U></I>. Except as contemplated in the Time of Sale Disclosure Package and in the Prospectus, subsequent to the respective
dates as of which information is given in the Time of Sale Disclosure Package, the Company shall not have incurred any material liabilities
or obligations, direct or contingent, or entered into any material transactions, or declared or paid any dividends or made any distribution
of any kind with respect to its capital stock; and there shall not have been any change in the capital stock (other than a change in the
number of outstanding shares of Common Stock due to the issuance of shares upon the exercise of outstanding options or warrants or conversion
of convertible securities), or any material change in the short-term or long-term debt of the Company (other than as a result of the conversion
of convertible securities), or any issuance of options or other similar equity awards, warrants, convertible securities or other rights
to purchase the capital stock of the Company except for the issuance of employee stock options or other similar equity awards not exercisable
during the Lock-Up Period pursuant to the Company Stock Plans, as in effect on the date hereof in the ordinary course of business consistent
with past practices, or any Material Adverse Change or any development involving a prospective Material Adverse Change (whether or not
arising in the ordinary course of business), or any loss by strike, fire, flood, earthquake, accident or other calamity, whether or not
covered by insurance, incurred by the Company, the effect of which, in any such case described above, in your judgment, makes it impractical
or inadvisable to offer or deliver the Securities on the terms and in the manner contemplated in the Time of Sale Disclosure Package and
in the Prospectus.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) <I><U>Opinion
of Company Counsel</U></I>. On each Closing Date, there shall have been furnished to you, as Underwriter, the opinion and negative assurance
letter, dated as of the applicable Closing Date, of Honigman LLP, counsel for the Company, in form and substance satisfactory to you.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) <I><U>Opinion
of Underwriter&rsquo;s Counsel</U></I>. On each Closing Date, there shall have been furnished to you, as Underwriter, such opinion or
opinions from Faegre Drinker Biddle &amp; Reath LLP, counsel for the Underwriter, dated such Closing Date and addressed to you, with respect
to such matters as you reasonably may request, and such counsel shall have received such papers and information as they request to enable
them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(f) <I><U>Comfort
Letter</U></I>. On the date hereof, on the effective date of any post-effective amendment to the Registration Statement filed after the
date hereof and on each Closing Date you, as the Underwriter, shall have received an accountant&rsquo;s &ldquo;comfort&rdquo; letter from
Baker Tilly US LLP dated such date and addressed to you, in form and substance satisfactory to you.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(g) <I><U>Officers&rsquo;
Certificate</U></I>. On each Closing Date, there shall have been furnished to you, as the Underwriter, a certificate, dated such Closing
Date and addressed to you, signed by the chief executive officer and by the chief financial officer of the Company, to the effect that:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i) The
representations and warranties of the Company in this Agreement are true and correct as if made at and as of such Closing Date, and the
Company has complied with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to
such Closing Date;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(ii) No
stop order or other order suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof or the
qualification of the Securities for offering or sale nor suspending or preventing the use of the Time of Sale Disclosure Package, the
Prospectus or any issuer free writing prospectus, has been issued, and no proceeding for that purpose has been instituted or, to the best
of its knowledge, is contemplated by the Commission or any state or regulatory body; and</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(iii) Affirms the accuracy of the matters set
forth in subsection (c) of this Section 5.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(h) <I><U>CFO
Certificate</U></I>. On the date hereof and on each Closing Date, the Company shall have furnished to you, as the Underwriter, a certificate,
dated as of such date, signed on behalf of the Company by its chief financial officer, regarding certain financial information included
in or incorporated by reference into the Preliminary Prospectus and the Prospectus, respectively, in form and substance reasonably satisfactory
to you.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(i) <I><U>Lock-Up
Agreement</U></I>. The Underwriter shall have received all of the Lock-Up Agreements referenced in Section 4 and the Lock-Up Agreements
shall remain in full force and effect.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(j) <I><U>FINRA
No Objections</U></I>. FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(k) <I><U>Other
Documents</U></I>. The Company shall have furnished to you, as Underwriter, and counsel for the Underwriter such additional documents,
certificates and evidence as you or they may have reasonably requested.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 1in">(l) <I><U>Exchange
Listing</U></I>. The Company shall have provided notification to the Nasdaq Capital Market that the Company intends to issue the Securities
and there shall not be any written objection from the Nasdaq Capital Market with respect to such notification.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">All such opinions, certificates,
letters and other documents will be in compliance with the provisions hereof only if they are reasonably satisfactory in form and substance
to you and counsel for the Underwriter. The Company will furnish you with such conformed copies of such opinions, certificates, letters
and other documents as you shall reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">6.
</FONT><B><I>Indemnification and Contribution</I></B><FONT STYLE="font-style: normal; font-weight: normal">.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) <I><U>Indemnification
by the Company</U></I>. The Company agrees to indemnify and hold harmless the Underwriter, its affiliates, directors and officers and
each person, if any, who controls such Underwriter within the meaning of Section 15 of the Act or Section 20 of the Exchange Act, from
and against any losses, claims, damages or liabilities, joint or several, to which such Underwriter may become subject, under the Act
or otherwise (including in settlement of any litigation if such settlement is effected with the written consent of the Company), insofar
as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i) an untrue statement
or alleged untrue statement of a material fact contained in the Registration Statement, including the 430B Information and any other information
deemed to be a part of the Registration Statement at the time of effectiveness and at any subsequent time pursuant to the Rules and Regulations,
if applicable, or arise out of or are based on the omission or alleged omission to state therein a material fact required to be stated
thereon or necessary in order to make the statements therein not misleading, (ii) an untrue statement or alleged untrue statement of a
material fact contained in any Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus, or any amendment or supplement
thereto, any issuer free writing prospectus, or any issuer information that the Company has filed or is required to file pursuant to Rule
433(d) of the Rules and Regulations, or arise out of or are based on the omission or alleged omission to state therein a material fact
required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made, not
misleading, and will reimburse the Underwriter for any legal or other expenses reasonably incurred by it in connection with investigating
or defending against such loss, claim, damage, liability or action as such expenses are incurred; <I>provided, however,</I> that the Company
will not be liable in any such case to the extent that any such loss, claim, damage, liability or action arises out of or is based upon
an untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with written information
furnished to the Company by you, or by the Underwriter through you, specifically for use in the preparation thereof; it being understood
and agreed that the only information furnished by an Underwriter consists of the information described as such in Section 6(e).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) <I><U>Indemnification
by the Underwriter</U></I>. The Underwriter will, severally and not jointly, indemnify and hold harmless the Company, its affiliates,
directors and officers and each person, if any, who controls the Company within the meaning of Section 15 of the Act and Section 20 of
the Exchange Act from and against any losses, claims, damages or liabilities, joint or several, to which the Company may become subject,
under the Act or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such
Underwriter), insofar as such losses, claims, damages or liabilities (or actions in respect thereof) arise out of or are based upon (i)
an untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, including the 430B Information
and any other information deemed to be a part of the Registration Statement at the time of effectiveness and at any subsequent time pursuant
to the Rules and Regulations, if applicable, or arise out of or are based on the omission or alleged omission to state therein a material
fact required to be stated thereon or necessary in order to make the statements therein not misleading, (ii) an untrue statement or alleged
untrue statement of a material fact contained in in any Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus, or
any amendment or supplement thereto, or any issuer free writing prospectus, or any issuer information that the Company has filed or is
required to file pursuant to Rule 433(d) of the Rules and Regulations, or arise out of or are based upon the omission
or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading, in each case to the extent, but only to the extent, that such untrue
statement or alleged untrue statement or omission or alleged omission was made in reliance upon and in conformity with written information
furnished to the Company by you, or by such Underwriter through you, specifically for use in the preparation thereof (it being understood
and agreed that the only information furnished by an Underwriter consists of the information described as such in Section 6(e)), and will
reimburse the Company for any legal or other expenses reasonably incurred by the Company in connection with investigating or defending
against any such loss, claim, damage, liability or action as such expenses are incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) <I><U>Notice
and Procedures</U></I>. Promptly after receipt by an indemnified party under subsection (a) or (b) above of notice of the commencement
of any action, such indemnified party shall, if a claim in respect thereof is to be made against the indemnifying party under such subsection,
notify the indemnifying party in writing of the commencement thereof; but the omission so to notify the indemnifying party shall not relieve
the indemnifying party from any liability that it may have to any indemnified party except to the extent such indemnifying party has been
materially prejudiced by such failure (through the forfeiture of substantive rights or defenses). In case any such action shall be brought
against any indemnified party, and it shall notify the indemnifying party of the commencement thereof, the indemnifying party shall be
entitled to participate in, and, to the extent that it shall wish, jointly with any other indemnifying party similarly notified, to assume
the defense thereof, with counsel satisfactory to such indemnified party, and after notice from the indemnifying party to such indemnified
party of the indemnifying party&rsquo;s election so to assume the defense thereof, the indemnifying party shall not be liable to such
indemnified party under such subsection for any legal or other expenses subsequently incurred by such indemnified party in connection
with the defense thereof other than reasonable costs of investigation; <I>provided</I>, <I>however</I>, that if, in the reasonable judgment
of the Underwriter (upon written advice received from its outside counsel), it is advisable for the Underwriter to be represented by separate
counsel, the Underwriter shall have the right to employ a single counsel (in addition to local counsel) to represent the Underwriter who
may be subject to liability arising from any claim in respect of which indemnity may be sought by the Underwriter under subsection (a)
of this Section 6, in which event the reasonable fees and expenses of such separate counsel shall be borne by the indemnifying party or
parties and reimbursed to the Underwriter as incurred. An indemnifying party shall not be obligated under any settlement agreement, consent
to judgment or other compromise relating to any action under this Section 6 to which it has not agreed in writing. In addition, no indemnifying
party shall, without the prior written consent of the indemnified party (which consent shall not be unreasonably withheld or delayed),
effect any settlement of any pending or threatened proceeding unless such settlement includes an unconditional release of such indemnified
party for all liability on claims that are the subject matter of such proceeding and does not include a statement as to, or an admission
of, fault, culpability or a failure to act by or on behalf of an indemnified party. Notwithstanding the foregoing, if at any time an indemnified
party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel pursuant to this
Section 6(c), such indemnifying party agrees that it shall be liable for any settlement effected without its written consent if (i) such
settlement is entered into more than 45 days after receipt by such indemnifying party of the aforesaid request and (ii) such indemnifying
party shall not have reimbursed such indemnified party in accordance with such request prior to the date of such settlement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(d) <I><U>Contribution;
Limitations on Liability; Non-Exclusive Remedy</U></I>. If the indemnification provided for in this Section 6 is unavailable or insufficient
to hold harmless an indemnified party under subsection (a) or (b) above, then each indemnifying party shall contribute to the amount paid
or payable by such indemnified party as a result of the losses, claims, damages or liabilities referred to in subsection (a) or (b) above,
(i) in such proportion as is appropriate to reflect the relative benefits received by the Company on the one hand and the Underwriter
on the other from the offering of the Securities or (ii) if the allocation provided by clause (i) above is not permitted by applicable
law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative
fault of the Company on the one hand and the Underwriter on the other in connection with the statements or omissions that resulted in
such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by
the Company on the one hand and the Underwriter on the other shall be deemed to be in the same proportion as the total net proceeds from
the offering (before deducting expenses) received by the Company bear to the total underwriting discounts and commissions received by
the Underwriter, in each case as set forth in the table on the cover page of the Prospectus. The relative fault shall be determined by
reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission
to state a material fact relates to information supplied by the Company or the Underwriter and the parties&rsquo; relevant intent, knowledge,
access to information and opportunity to correct or prevent such untrue statement or omission. The Company and the Underwriter agree that
it would not be just and equitable if contributions pursuant to this subsection (e) were to be determined by pro rata allocation or by
any other method of allocation which does not take account of the equitable considerations referred to in the first sentence of this subsection
(e). The amount paid by an indemnified party as a result of the losses, claims, damages or liabilities referred to in the first sentence
of this subsection (e) shall be deemed to include any legal or other expenses reasonably incurred by such indemnified party in connection
with investigating or defending against any action or claim which is the subject of this subsection (e). Notwithstanding the provisions
of this subsection (e), no Underwriter shall be required to contribute any amount in excess of the amount by which the total underwriting
discounts and commissions received by such Underwriter with respect to the Securities purchased by it hereunder exceeds the amount of
any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled
to contribution from any person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this Section 6 are
not exclusive and shall not limit any rights or remedies that might otherwise be available to any indemnified party at law or in equity.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(e) <I><U>Information
Provided by the Underwriter</U></I>. The Underwriter confirms and the Company acknowledges that the statements with respect to the public
offering of the Securities by the Underwriter set forth in ninth and tenth paragraphs and the first sentence of the eleventh paragraph,
under the caption &ldquo;Underwriting&rdquo; in the Time of Sale Disclosure Package and in the Prospectus are correct and constitute the
only information concerning such Underwriter furnished in writing to the Company by or on behalf of the Underwriter specifically for inclusion
in the Registration Statement, any Preliminary Prospectus, the Time of Sale Disclosure Package, the Prospectus or any issuer free writing
prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">7. <B><I>Representations
and Agreements to Survive Delivery</I></B>. All representations, warranties, and agreements of the Company and the Underwriter herein
or in certificates delivered pursuant hereto, including but not limited to the agreement of the Company and the Underwriter contained
in Section 6 hereof, shall remain operative and in full force and effect regardless of any investigation made by or on behalf of the Underwriter
or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons, and shall survive delivery
of, and payment for, the Securities to and by the Underwriter hereunder and any termination of this Agreement.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">8. <B><I>Termination of this
Agreement.</I></B></P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) <I><U>Right to
Terminate</U></I>. You, the Underwriter, shall have the right to terminate this Agreement by giving notice to the Company as
hereinafter specified at any time at or prior to the First Closing Date, and the option referred to in Section 3(b), if exercised,
may be cancelled at any time prior to the Second Closing Date, if (i) the Company shall have failed, refused or been unable, at or
prior to such Closing Date, to perform any agreement on its part to be performed hereunder, (ii) any condition of the
Underwriter&rsquo;s obligations hereunder is not fulfilled, (iii) trading in the Company&rsquo;s Common Stock shall have been
materially limited or suspended by the Commission or the Nasdaq Capital Market or trading in securities generally on the Nasdaq
Stock Market or New York Stock Exchange shall have been suspended, (iv) minimum or maximum prices for trading shall have been fixed,
or maximum ranges for prices for securities shall have been required, on the NYSE American, Nasdaq Stock Market or New York Stock
Exchange, by such Exchange or by order of the Commission or any other Governmental Authority having jurisdiction, (v) a banking
moratorium shall have been declared by federal or New York state authorities or a material disruption in commercial banking or
securities settlement or clearance services in the United States or (vi) there shall have occurred any attack on, outbreak or
escalation of hostilities or act of terrorism involving the United States, any declaration by the United States of a national
emergency or war, any material adverse change in financial markets, any substantial change or development involving a prospective
substantial change in United States or international political, financial or economic conditions, or any other calamity or crisis
that, in your reasonable judgment, is material and adverse and makes it impractical or inadvisable to proceed with the completion of
the sale of and payment for the Securities.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) <I><U>Notice
of Termination</U></I>. If you elect to terminate this Agreement as provided in this Section, the Company shall be notified promptly by
you by telephone, confirmed by letter.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(c) <I><U>Effect
of Termination</U></I>. No party shall be relieved of any liability under this Agreement arising from any breach of its obligations hereunder
occurring prior to termination of this Agreement as a result of the termination of this Agreement.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">9. <B><I>Notices</I></B>.
Except as otherwise provided herein, all communications hereunder shall be in writing and, if to the Underwriter, shall be mailed via
overnight delivery service or hand delivered via courier to The Benchmark Company, LLC, 150 East 58th Street, 17th Floor New York, New
York 10155, Attention: Albert Hanser, with a copy to (which shall not constitute notice) Faegre Drinker Biddle &amp; Reath LLP, 2200 Wells
Fargo Center, 90 South 7th Street, Minneapolis, Minnesota 55402, Attention: Ben Stacke; if to the Company, shall be mailed via overnight
delivery service or hand delivered to it at 7599 Anagram Dr., Eden Prairie, MN 55344, Attention: Dave Rosa, with a copy to (which shall not constitute
notice) Honigman LLP, 650 Trade Centre Way, Suite 200, Kalamazoo, MI 49002, Attention: Phillip D. Torrence. Any party to this Agreement
may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">10. <B><I>Persons
Entitled to Benefit of Agreement</I></B>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their
respective successors and assigns and the controlling persons, officers and directors referred to in Section 6. Nothing in this Agreement
is intended or shall be construed to give to any other person, firm or corporation any legal or equitable remedy or claim under or in
respect of this Agreement or any provision herein contained. The term &ldquo;successors and assigns&rdquo; as herein used shall not include
any purchaser, as such purchaser, of any of the Securities from the Underwriter.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">11. <B><I>Absence of
Fiduciary Relationship</I></B>. The Company acknowledges and agrees that: (a) the Underwriter has been retained solely to act as
underwriter in connection with the sale of the Securities and that no fiduciary, advisory or agency relationship between the Company
and the Underwriter has been created in respect of any of the transactions contemplated by this Agreement, irrespective of whether
the Underwriter has advised or are advising the Company on other matters; (b) the price and other terms of the Securities set forth
in this Agreement were established by the Company following discussions and arms-length negotiations with the Underwriter and the
Company is capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions
contemplated by this Agreement; (c) the Company has been advised that the Underwriter and its affiliates are engaged in a broad
range of transactions which may involve interests that differ from those of the Company and that the Underwriter has no obligation
to disclose such interest and transactions to the Company by virtue of any fiduciary, advisory or agency relationship; (d) it has
been advised that the Underwriter is acting, in respect of the transactions contemplated by this Agreement, solely for the benefit
of the Underwriter, and not on behalf of the Company; and (e) it waives to the fullest extent permitted by law, any claims it may
have against the Underwriter for breach of fiduciary duty or alleged breach of fiduciary duty in respect of any of the transactions
contemplated by this Agreement and agrees that the Underwriter shall have no liability (whether direct or indirect) to the Company
in respect of such a fiduciary duty claim on behalf of or in right of the Company, including stockholders, employees or creditors of
the Company.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><FONT STYLE="font-style: normal; font-weight: normal">12.
</FONT><B><I>Recognition of the U.S. Special Resolution Regimes</I></B><FONT STYLE="font-style: normal; font-weight: normal">.</FONT></P>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(a) In
the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution Regime, the transfer
from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent
as the transfer would be effective under the U.S. Special Resolution Regime if this Agreement, and any such interest and obligation, were
governed by the laws of the United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">(b) In
the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a proceeding under
a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent
than such Default Rights could be exercised under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the
United States or a state of the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> (c) As used in this Section 12:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>BHC Act Affiliate</I></B>&rdquo; has
the meaning assigned to the term &ldquo;affiliate&rdquo; in, and shall be interpreted in accordance with, 12 U.S.C. &sect; 1841(k).</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Covered Entity</I></B>&rdquo; means any of the following:</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">a &ldquo;covered entity&rdquo; as that term is defined in, and
interpreted in accordance with, 12 C.F.R. &sect; 252.82(b);</TD>
</TR></TABLE>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">a &ldquo;covered bank&rdquo; as that term is defined in, and interpreted
in accordance with, 12 C.F.R. &sect; 47.3(b); or</TD>
</TR></TABLE>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 1in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">a &ldquo;covered FSI&rdquo; as that term is defined in, and interpreted
in accordance with, 12 C.F.R. &sect; 382.2(b).</TD>
</TR></TABLE>



<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>Default Right</I></B>&rdquo; has the
meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. &sect;&sect; 252.81, 47.2 or 382.1, as applicable.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;<B><I>U.S. Special Resolution Regime</I></B>&rdquo;
means each of (i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall
Street Reform and Consumer Protection Act and the regulations promulgated thereunder.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">13. <B><I>Governing
Law; Waiver of Jury Trial</I></B>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York.
The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its stockholders and affiliates) and the Underwriter
hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding
arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14. <B><I>Counterparts</I></B>.
This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart, the executed counterparts shall
each be deemed to be an original and all such counterparts shall together constitute one and the same instrument. The words &ldquo;execution,&rdquo;
&ldquo;signed,&rdquo; &ldquo;signature,&rdquo; and words of like import in this Agreement or in any other certificate, agreement or document
related to this Agreement, if any, shall include images of manually executed signatures transmitted by facsimile or other electronic format
(including, without limitation, &ldquo;pdf,&rdquo; &ldquo;tif&rdquo; or &ldquo;jpg&rdquo;) and other electronic signatures (including,
without limitation, DocuSign and AdobeSign). The use of electronic signatures and electronic records (including, without limitation, any
contract or other record created, generated, sent, communicated, received, or stored by electronic means) shall be of the same legal effect,
validity and enforceability as a manually executed signature or use of a paper-based record-keeping system to the fullest extent permitted
by applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic
Signatures and Records Act and any other applicable law, including, without limitation, any state law based on the Uniform Electronic
Transactions Act or the Uniform Commercial Code.</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">15. <B><I>General
Provisions.</I></B> This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes all prior written
or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof, including
that certain engagement letter (other than Sections 1, 3, 12 and Exhibit A thereof which will survive), dated June 27, 2023, by and between
the Company and the Underwriter. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no
condition herein (express or implied) may be waived unless waived in writing by each party whom the condition is meant to benefit. The
Section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement.
The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability
of any other Section, paragraph or provision hereof. If any Section, paragraph or provision of this Agreement is for any reason determined
to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to
make it valid and enforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --> -</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 1in">Please sign and return to the
Company the enclosed duplicates of this letter whereupon this letter will become a binding agreement between the Company and the Underwriter
in accordance with its terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>NeuroOne
    Medical Technologies Corporation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 35%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ David Rosa</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David Rosa</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its: </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-variant: small-caps"><B>The
    Benchmark Company, LLC</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt; width: 35%"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ John Borer </FONT></TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="font-size: 10pt"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John Borer</FONT></TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its: </FONT></TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Head of Investment Banking</FONT></TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[Signature Page to Underwriting Agreement]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE I</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Underwriter</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Underwriter</B></FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of Firm Shares</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Benchmark Company, LLC</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,250,000</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE II</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Certain Permitted Free Writing Prospectuses</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SCHEDULE III</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pricing Information</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Firm Shares: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,250,000
shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Option Shares: <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">787,500
shares</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Price to the public: $ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.00
per share</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Price to the Underwriter:
$ <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93 per share</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>List of Individuals and Entities Executing Lock-Up
Agreements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">David Rosa</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ronald McClurg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Mark Christianson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Steve Mertens</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Paul Buckman</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jeffrey Mathiesen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Edward Andrle</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXHIBIT A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Form of Lock-Up Agreement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Date: ___________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Benchmark Company, LLC</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">150 East 58th Street,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">17th Floor New York</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">New York 10155</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 36.05pt">As an inducement to The
Benchmark Company, LLC to execute an underwriting agreement (the <I>&ldquo;<B>Underwriting Agreement</B>&rdquo;</I>) as underwriter (the
<I>&ldquo;<B>Underwriter</B>&rdquo;</I>) providing for a public offering (the <I>&ldquo;<B>Offering</B>&rdquo;</I>) of common stock, par
value $0.001 per share (the <I>&ldquo;<B>Common Stock</B>&rdquo;</I>), or other securities, of NeuroOne Medical Technologies Corporation,
a Delaware corporation, and any successor (by merger or otherwise) thereto (the <I>&ldquo;<B>Company</B>&rdquo;</I>), the undersigned
hereby agrees that without, in each case, the prior written consent of the Underwriter during the period specified in the second succeeding
paragraph (the <I>&ldquo;<B>Lock-Up Period</B>&rdquo;</I>), the undersigned will not: (1) offer, pledge, announce the intention to sell,
sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant
to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly, any shares of the Company&rsquo;s Common
Stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive Common Stock (including
without limitation, Common Stock which may be deemed to be beneficially owned by the undersigned in accordance with the rules and regulations
of the U.S. Securities and Exchange Commission (the <I>&ldquo;<B>SEC</B>&rdquo;</I>) and securities which may be issued upon exercise
of a stock option or warrant) whether now owned or hereafter acquired (the <I>&ldquo;<B>Undersigned&rsquo;s Securities</B>&rdquo;</I>);
(2) enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Undersigned&rsquo;s
Securities, whether any such transaction described in clause (1) or (2) above is to be settled by delivery of Common Stock or such other
securities, in cash or otherwise; (3) make any demand for or exercise any right with respect to, the registration of any Common Stock
or any security convertible into or exercisable or exchangeable for Common Stock; or (4) publicly disclose the intention to do any of
the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned agrees that
the foregoing restrictions preclude the undersigned from engaging in any hedging or other transaction which is designed to or which reasonably
could be expected to lead to or result in a sale or disposition of the Undersigned&rsquo;s Securities during the Lock-Up Period even if
such securities would be disposed of by someone other than the undersigned. Such prohibited hedging or other transactions would include
without limitation any short sale or any purchase, sale or grant of any right (including without limitation any put or call option) with
respect to any of the Undersigned&rsquo;s Securities or with respect to any security that includes, relates to or derives any significant
part of its value from such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The Lock-Up Period will commence
on the date of this Lock-Up Agreement and continue and include the date ninety (90) days after the date of the final prospectus supplement
used to sell the Common Stock (or other securities) in the Offering pursuant to the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Notwithstanding the foregoing,
the undersigned may transfer the Undersigned&rsquo;s Securities (i) as a <I>bona fide </I>gift or gifts, (ii) to any trust for the direct
or indirect benefit of the undersigned or the immediate family of the undersigned, (iii) if the undersigned is a corporation, partnership,
limited liability company, trust or other business entity (1) to another corporation, partnership, limited liability company, trust or
other business entity that is a direct or indirect affiliate
(as defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or (2) as distributions of shares
of Common Stock or any security convertible into or exercisable for Common Stock to limited partners, limited liability company members,
trust beneficiaries or stockholders of the undersigned, (iv) by testate succession or intestate succession, or (v) pursuant to the Underwriting
Agreement; <I>provided,</I> in the case of clauses (i) through (iv), that (x) such transfer shall not involve a disposition for value,
(y) the transferee agrees in writing with the Underwriter to be bound by the terms of this Lock-Up Agreement and (z) no filing by any
party under Section 16(a) of the Securities Exchange Act of 1934, as amended (the <I>&ldquo;<B>Exchange Act</B>&rdquo;</I>), shall be
required or shall be made voluntarily in connection with such transfer. For purposes of this Lock-Up Agreement, &ldquo;immediate family&rdquo;
shall mean any relationship by blood, marriage or adoption, not more remote than first cousin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, the foregoing
restrictions shall not apply to (i) the exercise of stock options granted pursuant to the Company&rsquo;s equity incentive plans; <I>provided
</I>that such restrictions shall apply to any of the Undersigned&rsquo;s Securities issued upon such exercise, or (ii) the establishment
of any contract, instruction or plan (a <I>&ldquo;<B>Plan</B>&rdquo;</I>) that satisfies all of the requirements of Rule 10b5-1(c)(1)(i)(B)
under the Exchange Act; <I>provided </I>that no sales of the Undersigned&rsquo;s Securities shall be made pursuant to such a Plan prior
to the expiration of the Lock-Up Period, and such a Plan may only be established if no public announcement of the establishment or existence
thereof and no filing with the SEC or other regulatory authority in respect thereof or transactions thereunder or contemplated thereby,
by the undersigned, the Company or any other person, shall be required, and no such announcement or filing is made voluntarily by the
undersigned, the Company or any other person, prior to the expiration of the Lock-Up Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In furtherance of the foregoing,
the Company and its transfer agent and registrar are hereby authorized to decline to make any transfer of shares of Common Stock if such
transfer would constitute a violation or breach of this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned hereby represents
and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement and that upon request, the undersigned
will execute any additional documents necessary to ensure the validity or enforcement of this Lock-Up Agreement. All authority herein
conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal
representatives of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The undersigned understands
that the undersigned shall be released from all obligations under this Lock-Up Agreement if (i) the Company notifies the Underwriter that
it does not intend to proceed with the Offering, (ii) the Underwriting Agreement does not become effective, or if the Underwriting Agreement
(other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the
Common Stock (or other securities) to be sold thereunder or (iii) the Offering is not completed by August 31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 35.95pt">The undersigned understands
that the Underwriter is entering into the Underwriting Agreement and proceeding with the Offering in reliance upon this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This Lock-Up Agreement shall
be governed by, and construed in accordance with, the laws of the State of New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>The remainder of this page has intentionally
been left blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 39; Options: NewSection; Value: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --> -</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed Name of Holder</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Printed Name and Title of Person Signing</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(<I>if signing as custodian, trustee or on behalf of an entity</I>)</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Page; Sequence: 40; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ea182399ex5-1_neuroone.htm
<DESCRIPTION>OPINION OF HONIGMAN LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 5.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">July 27, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">7599 Anagram Drive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Eden Prairie, MN 55344</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Re:</I></B></FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B><I>Prospectus Supplement to Registration Statement on Form S-3 (File No. 333-256830)</I></B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have acted as counsel to
NeuroOne Medical Technologies Corporation, a Delaware corporation (the <B><I>&ldquo;Company&rdquo;</I></B>), in connection with (i) preparing
and filing with the Securities and Exchange Commission (the <B><I>&ldquo;Commission&rdquo;</I></B>) pursuant to the Securities Act of
1933, as amended (the <B>&ldquo;<I>Securities Act</I>&rdquo;</B>), of (a) a Registration Statement on Form S-3 (File No. 333-256830) (such
registration statement as amended or supplemented from time to time, the <B><I>&ldquo;Registration Statement&rdquo;</I></B>), declared
effective on June 14, 2021, and the prospectus of the Company included in the Registration Statement (the <B>&ldquo;<I>Base Prospectus</I>&rdquo;</B>)
and (b) a prospectus supplement to the Base Prospectus, dated as of July 24, 2023 (the &ldquo;<B><I>Prospectus Supplement</I></B>&rdquo;),
pertaining to the issuance and sale by the Company of up to 6,037,500 shares of the Company&rsquo;s common stock, par value $0.001 per
share (the &ldquo;<B>Common Stock</B>&rdquo;) (which include 787,500 shares of Common Stock pursuant to the exercise of the overallotment
option), in a public offering (the &ldquo;<B><I>Offered Shares&rdquo;</I></B>) and (ii) the Underwriting Agreement, dated as of July 24,
2023 (the <B><I>&ldquo;Underwriting Agreement&rdquo;</I></B>), between the Company and The Benchmark Company, LLC, as the sole underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">For the purpose of rendering
this opinion, we examined originals or copies of such documents as we deemed relevant. In conducting our examination, we assumed, without
investigation, the genuineness of all signatures, the correctness of all certificates, the authenticity of all documents submitted to
us as originals, the conformity to original documents of all documents submitted as certified or photostatic copies, and the authenticity
of the originals of such copies, and the accuracy and completeness of all records made available to us by the Company. In addition, in
rendering this opinion, we have assumed that the Offered Shares will be offered in the manner and on the terms identified or referred
to in the Registration Statement, the Base Prospectus, the Prospectus Supplement, including all supplements and amendments thereto, and
the Underwriting Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our opinion is limited solely
to matters set forth herein. The law covered by the opinions expressed herein is limited to the Delaware General Corporation Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based upon our examination
of such documents and other matters as we deem relevant, we are of the opinion that the Offered Shares covered by the Registration Statement
and the Prospectus Supplement have been duly authorized by the Company and, when issued, sold, and delivered by the Company in accordance
with, and as described in, the Registration Statement and the Prospectus Supplement and in the manner set forth in the Underwriting Agreement,
against payment therefor, will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We hereby consent to the filing
of this opinion with the Commission as <U>Exhibit&nbsp;5.1</U> to the Company&rsquo;s Current Report on Form 8-K, which is incorporated
by reference in the Registration Statement, and to the reference to our firm under the caption &ldquo;Legal Matters&rdquo; in the Registration
Statement and the Prospectus Supplement. In giving such consent, we do not admit that we are within the category of persons whose consent
is required by Section&nbsp;7 of the Securities Act or the rules&nbsp;and regulations promulgated thereunder by the Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-top: Black 1.5pt solid; padding-top: 6pt; text-align: center; width: 100%; padding-bottom: 8pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Honigman LLP &bull; 650 Trade Centre Way &bull; Suite 200 &bull; Kalamazoo, Michigan 49002-0402</B></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left"><IMG SRC="ex5-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">NeuroOne Medical Technologies Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">July 27, 2023</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">Page 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 40%; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Honigman LLP</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Honigman LLP</FONT></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">PDT/JQW/EJJ/EAAL/SASC/RZK&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt"><P STYLE="margin: 0pt"></P><TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"><TR STYLE="vertical-align: top"><TD STYLE="border-top: Black 1.5pt solid; padding-top: 6pt; text-align: center; width: 100%; padding-bottom: 8pt; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Honigman LLP &bull; 650 Trade Centre Way &bull; Suite 200 &bull; Kalamazoo, Michigan 49002-0402</B></FONT></TD></TR></TABLE><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>ea182399ex99-1_neuroone.htm
<DESCRIPTION>PRESS RELEASE DATED JULY 24, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>NeuroOne Medical Technologies
Corporation Announces Proposed Public Offering of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">EDEN
PRAIRIE, Minn., July 24, 2023 (GLOBE NEWSWIRE) &ndash; NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the &ldquo;Company&rdquo;),
a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders,
</FONT>announced today that it has commenced a proposed underwritten registered public offering of shares of its common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">All of the shares of common stock to be sold
in the proposed offering will be sold by the Company. In addition, <FONT STYLE="background-color: white">the Company intends</FONT> to
grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the offering. The
proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed,
or as to the actual size or terms of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">The
Company intends to use the proceeds from this proposed offering to: (i) support the commercial launch of the EVO sEEG electrode with Zimmer
Biomet, (ii) support the FDA submission for the OneRF ablation system and (iii) complete the design of a novel drug delivery electrode,
among other general corporate purposes</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Benchmark Company, LLC is acting as sole
book-running manager for the proposed offering. Kestrel Merchant Partners group at The Benchmark Company, LLC is responsible for sourcing
and executing the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The proposed offering is being made pursuant
to a shelf registration statement on Form S-3 (File No. 333-256830) that was declared effective by the U.S. Securities and Exchange Commission
(&ldquo;SEC&rdquo;), on June 14, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the proposed offering
will be filed with the SEC and will be available on the SEC&rsquo;s website at www.sec.gov or by contacting The Benchmark Company, LLC,
150 East 58<SUP>th</SUP> St., 17<SUP>th</SUP> Floor, New York, NY 10155, by telephone at 212-312-6700 or by email at prospectus@benchmarkcompany.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release does not and shall not
constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in
any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including
a prospectus supplement, forming a part of the effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About NeuroOne</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">NeuroOne Medical Technologies Corporation
is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation
and ablation solutions for patients suffering from epilepsy, Parkinson&rsquo;s disease, dystonia, essential tremors, chronic pain due to failed
back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may
also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release may include forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward&ndash;looking
statement that reflects the Company&rsquo;s current views about future events and are subject to known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some cases, you can identify forward&ndash;looking statements by the words
&ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;objective,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;potential,&rdquo; &ldquo;target,&rdquo; &ldquo;seek,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;continue&rdquo; and &ldquo;ongoing,&rdquo; or
the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward&ndash;looking statements
include statements related to the proposed offering and expected use of proceeds. Although the Company believes that we have a reasonable
basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently
known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different
from what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions,
the satisfaction of customary closing conditions related to the proposed public offering, the impact of general economic, industry or
political conditions in the United States or internationally and those described under the heading &ldquo;Risk Factors&rdquo; in our filings
with the Securities and Exchange Commission. These forward&ndash;looking statements speak only as of the date of this press release and
the Company undertakes no obligation to revise or update any forward&ndash;looking statements for any reason, even if new information
becomes available in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contact Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">800-631-4030</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">ir@nmtc1.com</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>ea182399ex99-2_neuroone.htm
<DESCRIPTION>PRESS RELEASE DATED JULY 25, 2023
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>NeuroOne Medical Technologies
Corporation Announces Pricing of Public Offering of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">EDEN
PRAIRIE, Minn., July 25, 2023 (GLOBE NEWSWIRE) &ndash; NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (the &ldquo;Company&rdquo;),
a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders,
</FONT>announced today the pricing of an underwritten registered public offering of 5,250,000 shares of its common stock at a price of
$1.00 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">All of the shares of common stock to be sold
in the offering will be sold by the Company. In addition, <FONT STYLE="background-color: white">the Company has</FONT> granted the underwriter
a 30-day option to purchase up to an additional 787,500 shares of its common stock at the public offering price less the underwriting
discount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The gross proceeds to the Company from this
offering, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriter&rsquo;s
option to purchase additional shares, are expected to be approximately $5,250,000. The offering is scheduled to close on or about July
27, 2023, subject to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">The
Company intends to use the proceeds from this proposed offering to: (i) support the commercial launch of the EVO sEEG electrode with Zimmer
Biomet, (ii) support the FDA submission for the OneRF ablation system and (iii) complete the design of a novel drug delivery electrode,
among other general corporate purposes</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The Benchmark Company, LLC is acting as sole
book-running manager for the offering. Kestrel Merchant Partners group at The Benchmark Company, LLC is responsible for sourcing and executing
the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">The shares will be issued pursuant to a shelf
registration statement on Form S-3 (File No. 333-256830) that was declared effective by the U.S. Securities and Exchange Commission (&ldquo;SEC&rdquo;),
on June 14, 2021. A preliminary prospectus supplement and accompanying prospectus relating to the offering was filed with the SEC and
is available on the SEC&rsquo;s website at www.sec.gov or by contacting The Benchmark Company, LLC, 150 East 58th St., 17th Floor, New
York, NY 10155, by telephone at 212-312-6700 or by email at prospectus@benchmarkcompany.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release does not and shall not
constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in
any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under
the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of a prospectus, including
a prospectus supplement, forming a part of the effective registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">###</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>About NeuroOne</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">NeuroOne Medical Technologies Corporation
is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation
and ablation solutions for patients suffering from epilepsy, Parkinson&rsquo;s disease, dystonia, essential tremors, chronic pain due to failed
back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may
also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Forward Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">This press release may include forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward&ndash;looking
statement that reflects the Company&rsquo;s current views about future events and are subject to known and unknown risks, uncertainties and
other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information
expressed or implied by these forward-looking statements. In some cases, you can identify forward&ndash;looking statements by the words
&ldquo;may,&rdquo; &ldquo;might,&rdquo; &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;intend,&rdquo;
&ldquo;plan,&rdquo; &ldquo;objective,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
&ldquo;potential,&rdquo; &ldquo;target,&rdquo; &ldquo;seek,&rdquo; &ldquo;contemplate,&rdquo; &ldquo;continue&rdquo; and &ldquo;ongoing,&rdquo; or
the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward&ndash;looking statements
include statements related to the offering and expected use of proceeds. Although the Company believes that we have a reasonable basis
for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known
by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control, including risks and uncertainties related to market and other conditions, the
satisfaction of customary closing conditions related to the public offering, the impact of general economic, industry or political conditions
in the United States or internationally and those described under the heading &ldquo;Risk Factors&rdquo; in our filings with the Securities
and Exchange Commission. These forward&ndash;looking statements speak only as of the date of this press release and the Company undertakes
no obligation to revise or update any forward&ndash;looking statements for any reason, even if new information becomes available in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><B>Contact Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">800-631-4030</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="background-color: white">ir@nmtc1.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>ex5-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex5-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  < +0# 2(  A$! Q$!_\0
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MD_:?TK5_@C\7O!$5WKOP(8ZYXQM? ATFTQ\=_AQ@'_A%?B)XU;+]!@* 3R5
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M'?B?^R+SP%\7OA_H>W0OB$-/\6+X=,3,!XK73'\6LLB)L\H _?[_ (9<T_\
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MPF64E$(&Q #]9/\ AF'2)$$O_"_?VH?+QQ_Q??Q %Z^N,#Z9S4G_  RYI_\
MT7G]J?\ \/MX@_PKXL\=_L2>*?#7[=_[&7[1_P "_'/CSPS\"_!GBSXQ6OQV
M_9OTCQEX@3X+@^._@1\2?#/P^^+/A_X>A4\(Z-XHTSQ;CP_XJD55W)XF5E'
M=_F[_@N'_P $YO#O[;WP1T?1?AKIA\*?M2:IJOQ'O?A3\2O"%^?#'BGQ-XG\
M/_ ;XC^)=!\"^+/$/AP ^)/"OC)O .@>#@GC"1Q$D:&)D<;% /UD_P"&7-/_
M .B\_M3_ /A]O$'^%'_#+FG_ /1>?VI__#[>(/\ "OR@_P"#?G_@H^/VV_\
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M:Q\.%"7=6$FK#<H!+#U3_@W]\87%G_P31_9L_91^+OPB^-?P:^+OPF\%>+_
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M>TH.S^8J_)O_  2-U?QY^R3^Q)X#_8#_ &\OA%XQ^&OQ*_9XM/&/PQ'B+4/
M>N>/_@!\</AJ->\0^)/#FN?#SXG>%M%\:>$M:5_"^OVF@_\ "OO&@\#>/6 9
M6^'X&P5^O?\ PR]X._Z*-^T=_P")+?&__P";BG_\,Q>$?^BD?M'_ /B2WQO_
M /FXH _E=^,7_!,WQ/\ &#_@OM^RG^U'X _8R\3+_P $\6T>QT_XVWMYI>@>
M!OA9XF^,'AOP'\5O$_AWQAKWP&/]F^,!X5'BA?@Z?^$OU'P,? ?CWQ[X9(:1
MP69OW+_:C_:R\ _ 3X\_LE_#32O@=^T-XIT'1O'_ (EF\;^)/@M^S)\6?''P
MJ^!_@_\ X51XE\-:%KWBO7O#'@@Z#8^%7\4>(O#BK_PADDA7&XQ;8VW_ &O_
M ,,Q>$?^BD?M'_\ B2WQO_\ FXI__#,OA#_HHO[1G_B2OQP_^;F@#^=/X6?\
M$V?C1\ /^"X7Q@^//P-CO=!_X)S_ +;W[/>H_'S]H_3;;2-?MM"G^)6CZ[X=
M\07W@+2M*)C.D^)_&'BJZ;QD P8'X??$;XM?#Z-"ZI7S=\4_&GCNY_X.>?@5
M^V3I_P"S5^UGK/[*'@?]GFY^ 7B?X[Z'^RY\;[KP!:>+O$G@3XJBRU]KP^!E
MQX7;6OB%X<\(-KZJ0'+ ,ZJKG^K?_AE[P=_T4;]H[_Q);XW_ /S<4_\ X9B\
M(_\ 12/VC_\ Q);XW_\ S<4 ?GY^VC^V#HDGCOX)?LQV?PX_:L\0^$/C7X@T
M_P#X7/\ &[X4?LY?%F\\+_!CP"=";Q+X>_X2/Q%'X586+>-/%#>'/!VN8>2+
MP'X#\0^*Y/B(D17YOS2_X.,?V(]<^)W[*7@;XE_"#QI^TE\4/VR_V:/B1X9^
M+_[,.D^'O ^O?%/QCJ!/B?PWX:\?Z%X>L_AC\+L^&V5?^$<^(!8L 6^&R'9L
M+*G]#'_#./A#_H?/VA__ !)W]H'_ .>/6K_PR]X._P"BC?M'?^)+?&__ .;B
M@#Y1_9>_;SL?B7^QYX+^/OQF^%'Q[^#?Q1TSP'X?_P"%W?!C6/V=?C:OCWP[
M\21H-VOB'0O"GP__ .$$/C/Q1HA\3^'_ !$/"0\(1R*PC56*$G-?]@;XZ>#_
M -J#]E?PAX*\<_!CXL_#?7+_ .'-]X<^)/P(_:5^"_C+P%K%IHY)\-^(M-\1
MIXH\*+X/\3:%XO(! 1W,FD:PRE.0K?7/_#,7A'_HI'[1_P#XDM\;_P#YN*9_
MPR]X._Z*-^T=_P")+?&__P";B@#^:#X+?\$EOVA_^"7_ /P5;^"FL_L<:IK>
MM_\ !+S]JSXH^(]>^-WP7,S>(8?V<?BOX8^$_P 2/$/P\UX Z>#8^%CXJ_XI
M'X?^,B""2/AW\1F<'P%K$G]27QH^+GACX%?#CQ-\3O&$>J7'A[PEI_VZ_&CV
M+:GJF!QPF=I/( SCCVP#QG_#+W@[_HHW[1W_ (DM\;__ )N*FT[X ?#N30O$
M_@S7/^$Q\<>'M1U+0WNK#XE_$/QS\3E=K(6K0$-\0/$'B,C#+EN#N))X." #
MI/A[\5_#_P 2O!?AWQQX<@UNQTCQ+I5EK5K;:IH-VEY&NKV\>JXD7H/EO5QC
M@G)  .**ZKPUX#\'^!=&M/#7ACP_INF:-8*1:V<4 *1!\%L$G/.!^5% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>nmtc-20230724.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qA5s7xRiXgen8uKa3EsWa+G+aPtzply+ZlBtmd/bckqzygt9zBZCyYK4HN2cVgH -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:NMTC="http://n1mtc.com/20230724" elementFormDefault="qualified" targetNamespace="http://n1mtc.com/20230724">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://n1mtc.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20230724_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="nmtc-20230724_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
    <import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
    <import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
    <import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
    <import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>nmtc-20230724_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>nmtc-20230724_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.19a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://n1mtc.com/role/Cover" xlink:href="nmtc-20230724.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://n1mtc.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140027685102624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Jul. 24, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 24,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NeuroOne Medical Technologies Corporation<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001500198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-0863354<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">7599 Anagram Dr.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Eden Prairie<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">426-1383<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NMTC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>ea182399-8k_neuroone_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="nmtc-20230724.xsd" xlink:type="simple"/>
    <context id="AsOf2023-07-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001500198</identifier>
        </entity>
        <period>
            <startDate>2023-07-24</startDate>
            <endDate>2023-07-24</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="AsOf2023-07-24">0001500198</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="AsOf2023-07-24">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="AsOf2023-07-24">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2023-07-24">2023-07-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2023-07-24">NeuroOne Medical Technologies Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2023-07-24">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="AsOf2023-07-24">001-40439</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2023-07-24">27-0863354</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2023-07-24">7599 Anagram Dr.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2023-07-24">Eden Prairie</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2023-07-24">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2023-07-24">55344</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2023-07-24">952</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2023-07-24">426-1383</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2023-07-24">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2023-07-24">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2023-07-24">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2023-07-24">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2023-07-24">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2023-07-24">NMTC</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2023-07-24">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2023-07-24">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML0(  .(,   -    >&PO<W1Y;&5S+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9
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M8*<D3?,\C@ 69Y"F& *G$4<P!L !0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0
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M3R54&*!\4YFHO/93;#GICEYG>O\P>=0>6N=6RKV'5[+E&''\GN4/4$L#!!0
M   ( $^ ^U8D'INBK0   /@!   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'.UD3T.@S ,A:\2Y0 U4*E#!4Q=6"LN$ 7S(Q(2Q:X*MR^% 9 Z=&&R
MGBU_[\E.GV@4=VZ@MO,D1FL&RF3+[.\ I%NTBB[.XS!/:A>LXEF&!KS2O6H0
MDBBZ0=@S9)[NF:*<//Y#='7=:7PX_;(X\ \PO%WHJ45D*4H5&N1,PFBV-L%2
MXLM,EJ*H,AF**I9P6B#BR2!M:59]L$].M.=Y%S?W1:[-XPFNWPQP>'3^ 5!+
M P04    " !/@/M699!YDAD!  #/ P  $P   %M#;VYT96YT7U1Y<&5S72YX
M;6RMDTU.PS 0A:\295LE+BQ8H*8;8 M=< %C3QJK_I-G6M+;,T[:2J 2%85-
MK'C>O,^>EZS>CQ&PZ)WUV)0=47P4 E4'3F(=(GBNM"$Y2?R:MB)*M9-;$/?+
MY8-0P1-XJBA[E.O5,[1R;ZEXZ7D;3?!-F<!B63R-PLQJ2AFC-4H2U\7!ZQ^4
MZD2HN7/08&<B+EA0BJN$7/D=<.I[.T!*1D.QD8E>I6.5Z*U .EK >MKBRAE#
MVQH%.JB]XY8:8P*IL0,@9^O1=#%-)IXPC,^[V?S!9@K(RDT*$3FQ!'_'G2/)
MW55D(TADIJ]X(;+U[/M!3EN#OI'-X_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_
ML;S63AI_YHOA/UY_ 5!+ 0(4 Q0    ( $^ ^U8'04UB@0   +$    0
M          "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ 3X#[
M5C/X/&?N    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N
M>&UL4$L! A0#%     @ 3X#[5IE<G",0!@  G"<  !,              ( !
MS $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " !/@/M6.+;,=U,$
M  "2$   &               @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N
M>&UL4$L! A0#%     @ 3X#[5I^@&_"Q @  X@P   T              ( !
ME@P  'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !/@/M6EXJ[',     3 @
M"P              @ %R#P  7W)E;',O+G)E;'-02P$"% ,4    " !/@/M6
MJL0B%C,!   B @  #P              @ %;$   >&PO=V]R:V)O;VLN>&UL
M4$L! A0#%     @ 3X#[5B0>FZ*M    ^ $  !H              ( !NQ$
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 3X#[5F60
M>9(9 0  SP,  !,              ( !H!(  %M#;VYT96YT7U1Y<&5S72YX
8;6Q02P4&      D "0 ^ @  ZA,

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea182399-8k_neuroone.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://n1mtc.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ea182399-8k_neuroone.htm">ea182399-8k_neuroone.htm</File>
    <File>ea182399ex1-1_neuroone.htm</File>
    <File>ea182399ex5-1_neuroone.htm</File>
    <File>ea182399ex99-1_neuroone.htm</File>
    <File>ea182399ex99-2_neuroone.htm</File>
    <File>nmtc-20230724.xsd</File>
    <File>nmtc-20230724_lab.xml</File>
    <File>nmtc-20230724_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ea182399-8k_neuroone.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "ea182399-8k_neuroone.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nmtc-20230724_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nmtc-20230724_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nmtc-20230724.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 22,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "NMTC",
   "nsuri": "http://n1mtc.com/20230724",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea182399-8k_neuroone.htm",
      "contextRef": "AsOf2023-07-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://n1mtc.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "ea182399-8k_neuroone.htm",
      "contextRef": "AsOf2023-07-24",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://n1mtc.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001213900-23-060256-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-23-060256-xbrl.zip
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MW,J0Z2K\=4XTVK_I4<UF3P"U?01$/K[)W7@F0<*$1T^!D;]I#ZC%[)O\C;"
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M.,MJ3Q]$6Q4"/""?]&G(&_R2&>DC/=C2P2V8*3BR'M< "L55@ 'O FJY=(Z
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M\ZYC=BJX@0NA9=-+OG@K\GW/<E'^I\NMZ#ZR!PZ-R@6S5O2$F8K>6Z&N+9;
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M:Y>3UJN;<B6JKZ7LW!L6X)9MWLKJPUD;:CPB>TUNT]55-2DKWF%.62F&("O
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MDQ]QBL6&\/YW?BX-1)%<&.D%'>3CT7,4J_\1L>I/@:(+3%*]Y?"?ERGG0QQ
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M^&7_#(3#ATXS^^)Z#GSW)(P_WH8K7+CBQ]MPQ9]U[CR!<V>'VD-7MHB!>,S
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MG7P#Y19#(6QZ:U#?&=WCT8NN(-:H<9F%=&ZR .VHLHATN"-T)<7JG,&>R%#
MJG)]>L;AE 6*CY-:!7:XG0$+C@+X+"6=B#"']]4:SSP7+L&\5&(P0&;L!T%*
MR[L/:GG9\:N0!"] =!.$/<C(TB0V):HJ<_EY:Z4))$O-+;U(C#H61M*>P1$
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M!O.T)*Z.(E2/5 K@91B1;W%'RK"IC$A(&Y+!739$1+7.J:R;?9_4\HI9U.S
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MX96#@<M)-AEZ!<9="@@#.W,S+S0G[WW%6,Q$-\A&O1)$PX8XJ5V*,_0HBZ1
MT$1/.*+G* +G6XIJY:1*/YYETTQ_TY2(&NXX(U_B(-T6 * Y:04]!4;:"17C
MP#W U\]T,,-1.,$!'8('N:Y5S/!"VQ'&3SMZNA$ZNO],E^!$%?,$*11$U[K
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MG1+[IW];PJTM*9IRCDW=\45+?O=\/2.N@G(YA04K4GL*('H2=2/VIYW1'$J
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M#)'W=1$2&)48 B?[5>D--Y;=O#\'7W,\^A_!4/D9'@ ]>NKQ@%P5]UFL+1=
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M+LY*SXY!QXBU/TW=U3)-"BEF<_V*[JMK(-5E^L6=0_TB;'C-Z4ZN:$2\<N,
M4#CV69YD2.4Q3Y:P62G 9Q"<<?1[F4F967J.G:0H'F?:[-J!H\W+#9FU&C0V
M=7''" ,(&%]-MQ<,/!'[J .PXQ@S1_&?R7%K+LJTZ[,M&Q^H"-<^UAABJ,M%
M4A&Q)-UQMXF@%N?:I\@4C$O$=A(A""U%X*4PUZ'),B5F?4(8H$??@Q-GIMH\
M3T^IA' [CG_G'L0A$?&]NX=/HA<6'B'=Y-@R,?&>\2CH I]PQ'IS;%M,\4:"
MR6%87.I\&=06M /N@!;[:R3'(]PV#J7$$+[!V188@VU&KO/K/G,P^T9;";5F
MN1=+KR49K6*&';LG=ZH:*-W06SJP12+:-1F!2%#!^W4V,]I<,RMSP@V*MJ<%
MPNR!C3)V_#G,!K@N[ZWR!F*8L\+CRO\1A:>RVE]P^\6%!Y.'UU0)<X5"#/:3
M+E);B &"8N3-$2NX9B.=P,="P;'IJ90#D79P+3F,IV)!K5G3U[K%M&C!G#63
M>4I.2@\BIX!%_:KVC9WJ)1)*(9U4C>V[H%6^".$QV@$:2(CA!+_ \RK&,[\C
M7 A=]A$ ?!21@K> MXZ"MU%";W_![F-&6:N-L($H^V,!C^4K*H!JLW12=IG.
M)W&QZ?01+*\XL3A"6B(]+ /U'\3/6@D%"J>551][27-6E>O3,T$AV.8J*%68
M<I0#R_2-T]/S,8K0-$7)()&NF[*<J\E2I8;X1<("1G'XX4[1=FLU7"6PNHNE
MVM\96+6(E8F /]A+)S<PA.-K'H>L93-[PWD&W#RQVH/YI>1V&S85.8VSV9CV
MP.'0D ;;8]"2CK8;TE98KV)#X]T#(YI)!0*>. H(?@$;VHZYQWR6SF;6W/\4
M\SG^'/L9?Q?P3GDK.OKJ1O0G:,PO9D2+ANJSHJ.O;T2[IF(#AL]7-**IZ]N
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M#2^D_D#_SY@($P7J8'](L>ZY^J<9'^8GPGSCW/J4JZAZ8)V]%/](V ?FR81
MP"3EB'/%!'&67!@.$$2R"K,),V&YPC$4W=DL0]&=X.E09+G"#_2W-"/0+8=/
M P(=PB8HDD,C^PR0D>8A(OC :B:N(F=@ C-D=6!4!?KWD&!96-;2 $$_F%,B
M,+!T LODV,?00H1JAJ J?=BPA57!(!C_ _%^<"EN+=X'6WRF  BF1207C@7A
M:&BR","RS-)W+%.GX87$$-<@W9?'AW5=BJ?#/*PT(W@0PAQ23[<BPF"\#M9W
MELB)%+45V1X<BEN9=\)P-=Z06#H&_U>$B'\U1?GSPFB9,-.L#GQO?:W5:SMD
MDI(XL+C<>A.C.+TREX@2V8R4SNTH8;&!GQG+S@)%1ZV1C.%6(.W#GA\)+DXI
M)99#6Q^51TUX+UICJP71Q#869"'(3#9(PSZ+PB#R$)R+- DH9)B=UT^0@2X3
MH<J"G,A:09(T&S8,HR22BI295@!5C!D)OL++1J5SO.>T-MOFM/O!& 5"#H_:
M<T9+H6-3P29R%=!HF.7"=2IP+O:@""/).LUWM;-LO6WJ:;:?2 ASK:VV7-YP
MQC2/7DW9^L+2*K1BZ"-?)W"^5T6C,AW#ZI&@LZXJ6L>ZABM+@CN;I^% 8<8&
M##=855O$2$404T*A2P2-<.D1>J<Z?;:<LUHA/&F#<(QJ@W[/0#P(/8J039IY
M!V6,/QEAGPM_ T:(>,K$Y*AN);Y_RBQH,Y6);3F4KWQB4')"D!4Z1;9F5 .3
MVXX:;Y!//1D'A*9I\+4JZP7:FLARTX0 M@B;=/I:J3=I[MWZ+=1P,=L$O:[^
M+5_[<B+Y )O[K0'V3AY#=L& \+5(P;?IHX:26/$>+[34N,L50+.2*F!>*IYL
MYC+D*R.QX<["IMP$S%>!KR D33164&,KS%NVMPU-FMFT5W7$*X),IBEZ)WAW
M@09FL?0UJ10<QEKP2.$;@_]5!(+W;E0 ?3<.XP Y)7<Z;?C%'5*MYL*+Y5N$
M54/"=IWHDCW$T)M$PK!="",7V;EB"EH66(/CTU;VO'+%4-BS0L#62GY!R75\
M-0+P-<GQE&F^WI):=UG-VRH<+3QMPB]PBA'XG-!%P63K@ZY&2E"PW\ 2NPZ'
MI"_POS ) C.7,YZG199K@#OV!<@64(Z!S1E?':%\*P0!]HF0CK/Y#1^EE\);
MP_I#B.^NY/FBXA 3#I:%5!]\SI"E#E08@P>O9;%?9"#Y62;D*V2ET30%YG?:
M.YP%7@%KTO@.0]E79VXUP-Y@"'LV48-S >Z#L]79+H&^&_HZ:U?WF>6UN[.Y
MR3P C+W8GK(?9))F> &"D= O-+LS^W7D&51MT1^R^JI6'EW]LGQJ36<LJ#,.
ML)4E0W&GE=5.6"H740D=O5F0;MKDJ 6,_2KQ$0M9L?I[BM.T;MHS%9*5V]W#
M$\0A*'@A'B"EVC  0A$E<@,RX1I(D^)Z1.-R61Y:?[0M/V*H>7\1<5%Q5GLE
MDPB7E>Y(6)C67;M$X1D$RARTD"X;V</%K\66&^7*6FSG4V^3UI]MIH^/%&PG
M0BHSAB;+I.9%^X#\JW7N=.W;&FG=LJ6UP96TOU(/XBCX1C1HQ!M-4@/J2#B.
ML(Y%G(/@1 18#Y(;RS!I<4H;L.&<(.ADD:)9.&,]-'9V5:=I6'(> X*("D"E
M8>W&I>M'2>)C;"9-0\R^X?GR54 ']Y^ VM-@G.2"USX,TPQ1<%&Q/!_:R$5B
MX@]QW<Y\\T*IXD]OJ>+5XB<^GG!,M\5.X?3ZC GLE@TQ<J&,@VU!Y8)QC-"O
MFF!&AU[P>K5B;1G[='@A5NZ;:C@551M1SV/:%L.<DPC45>GZ03*FTY_H5B&%
MUC X/;#%'3X[:DB/57/AJS)4,X2;M!^%V8A] G%25>C:%4H'C6J,HW=:7EG/
MGT=>7(MH\GQ <69#"H]&&B9:U#V56.'OR%#J=OK;[[NM01LL.EC]UD$;'!1M
M+-DW26GM'+UT<+NAOYTMN#SE>\;>15HLS\%)<0Z$8O(L#9/0A-?J40OAA[*^
MC_8]80[WK95&\W"(XY64ETI0V$CHI6UA PW,/?8A%2XXPVNK.UU;"Y?'AS9%
M D6NDQ1N_"(?)2D+HPD#R+.22O C-]Q(DLG0C"XYIY%<XAVHF6XV@*@8GCP2
MQ&['DZ@77MWZ"B=<%JZT&*F:'8)Z5PT"?KV(R<+OY[36@COZ:AQ74);#(L6%
M\BSD\ZKK:B/#$NJKLGWA9A%#4P6AF0E<91Q9]/[D>(,?#&!/J8!<1[Q-'FMH
MY:=*7DC(3.CH591X[RU"&L^Y"9/(4\H*+UDF#&NV!%_-[E9#S[(M.B$'3B-Q
MZW#V2'$/5K\$MCYRD#B3Y%8HTXQ*P4H#DP.:X8C0H^E2PO,/:JXA3TTQ,U.X
M<*?O<2_2=#U9":L=7IX5:3 -Y-YHUD8Q</;QBM5S858 HBT *1._A-PSE58T
M?]'D)J"LKSWMBE?73BL]A;PL ,V!2?UGKO .P@^C($S)4V:EA2P;>J^\G$*Q
M]9>\6FDV1!Z9\&],77YPY1!K6W(G9)-8&Z?LC4;A#0WMH%*#8#*&9-S4G'3*
MZ80Y2"O\E4,"<'F3^ C5FKFO52S5-499<Q35/$V O)F,",2!3+IP...[ZVNM
M2F9$LS-D%:(1X1AQF([!X\R#D(#)K\CG[9N/H!VLKM6)=T>#97H'OY0BS07/
M?%Z46?*L2>17#!&.,)8BT"$O"0:?HD HMO:+:PP\;7:9&.4!3\;F]L;.X]2(
MJ1<O=CIL:0TSUMV<19P9R*<=-62!=2%FVS(*R8HP*/2O^>IMU"9"RU?FM73G
M$EOR93F;V?)EK:S-7G)%SN/8"UD=R'V.P1,R3G2Y 5;[X-H&,8W:Z8,K]OUU
MD9SL[#G<HISMXLLDN*N93S9WYD?$FD)0BP;$?H@)?"I06070K Z;]0-4W\S.
M/0?_JT0D?D]&E9V9C"H*_$D!/RTS/OCAR88':Z+[(,?O.8+L+4I<H'#HFL_%
M\Z(1L0?:A"2P_%?],*;U\^ QF;:0RQO[>1I2U!NU'E[ GRF)^SSGLO)]N(>4
MK4[D&[,U*UQ=#<+\M!;X&8G/0QUC]#FNPCRB WU. 2=B!Z[ ES^?V;7 5<!@
M,<\!2Q0&(/")'^)WJ20EX"Z*V.D'X(<-N313RGTH>[5ZRI$G[D!L=2P'X@Q[
M'I]$!OV1[%7,T!Y\._K73_C#YZLO9_##_P-02P,$%     @ 3X#[5D:TO H>
M"0  22P  !H   !E83$X,C,Y.65X-2TQ7VYE=7)O;VYE+FAT;>U::U/;2!;]
M[BK_AQ[7#@55-A:81P*.JXQ-$HAY#'8F-?MEJRVU[9[(DM(M89Q?/^=V2WXA
M'K,+8;))/D D==_GN>?>EJB_[YUU&L5"_?UQLXW?C/[5>R>]SG&C7K6_\;2:
M/JX?7;3_8-W>'YWC-Z5!&,0';,N)8M:38Z'9N9BPJW#,@[*]469=H>2@A(W8
M>OEW]QVR,5=#&53B,#I@6#Z[T0_C.!RG]V)Q$U>X+X?! 5-R.(I+C?I1X_AF
M)/LR9KN;6_7J$7RY_'96N"*(A2HUUH*^C@Z?0[7Q$[<>ML47 PK(R=D[UKUJ
MO2F)F]W*UG\<9VOSSVA88LU.[TVI]'V'QZB@6.0I.4W\*=O>+[-M9[OVS+J>
MU:$_$QW+P;34.!>)"B\"P<Z$)UWNLYYP1T'HAT,)T:U01:'BL0R#YS9D?_?U
M:]8,^%#Q,6LK>2V>6^.Q)P)VJ;A44I39V3G;W:WM[#RWUI6T]II'G6/6.NYT
MNI?-ULGYNS<EIV2N+YOM=G;]MRV92"\>T5+GUT/6#Y4G5,4-?9]'6@!BZ?]*
MAJ/KO:M,P;50,:$@LQIE6$IYO-YK9ZM2X<[FK@QRO3QD9&E%RZ_"FCMWN]=^
M&GGUMQ?GO<6X5 9\+/WIP4/= VQ>/VE<B8-Z]:1AR9Q$-?)-^R;&7*I01\*-
M$\VZ213Y8@P*0.S9E1A*'=OZ8]V8Q_8)+MZ&:LRZE1I;?RM]P<[#35:KU2K;
MNWNO:LY&GFOX<6737368:WPSB/^O6NS/>\!A;LH Y0SQ%;.RU.APCQB,!QY[
MAP<FJ <O;-.S4CKUYA6]J=I/@HWXM6#<C87'N$;])X$6/B!6+#RZ 9099VWA
M\PE7 A)F]]EZ/!+,(GG-][XDX6$K'$<\F*XI<Y6A<:/,9("=00"LT\:)C$=L
M76ZP2(F(*QD,BP7*UT#Z^+]]3+*[PDV4C+-T'M^X(QX,!8P;CZ76=]J0/EPU
M@T6)T@FW);8BO^FBO ;%PM;K6JU,H>* C8>H90I2Z="SO(NDSQ097\,!6^<;
M"-I_6\5L72?NJ%A0B_OU;/^"<:%B>D8<N!ZH<,QB ,=XB-]E=BL^^5;=3IDG
M7!\9]XH%,1A0X@ D[#A- )FM'3,);95-7DA%-*<R^$]W4BP@]:Z?D+'  -V_
M(RJWXWS$M6!SBEP-M(7,>I\BO:!=+Q$I"5V1 \]X6@ZPU YVUIV:-2*SX&Z*
MSJ*4FK-1+A8B-% N X)OJA88!-9<84*D.=+<GRX%!MJ3B%;OE9W:?GG7<9@>
M(>*K$5Q3FK10]8['!@FA^[G,4#CLFON)8/]R-C&),YA0+!@)JWZT[,8N;5RT
MFZU/1M(=92EB^Z]6S5C<>:M\Q(U0KD1P4WM#3!'<]\.88E0LA!&EV!8_4I3T
M?>EBZ4!0P>>$^H(>(3%=H_U6\9IL2Y &;?P(^*L)52%$-8=*F+SDI[98F.=V
MJ1+RA=RNA+Z()T($2\DC:WH$+A&X(Y#SY^Q)F74Z+<,@M%R'R'N2Z1%J\WFG
MS/PV\$+=!R1GJ2%!R[ H441;EN_CD426(I0,=9@)H0FC4V!(34(9]S71FXLE
M%HK$B<P+W822I"G V.11SCS(]<4UD+G)3DRC\1+7)#5,5"HW[638PE&7V%,V
M;29, %097 N$;YBN(9N'(DA@3""TT0U4,PUW>9PH"@LM02=4((;%)2Y-T0,T
MTSA;Q!/\##!:RWB:K9K[H)/^6,:$6&K(B7%JYGVF)1B@6=!V5%WV<$'&/4*I
MX5N+;*N(1F$<4A]!'=JXSOE[T5"4;EK0\TRD\;^US44OY*ZM!_ 3"#)>BAI"
MA$.(!H+ +_R:2Y_W?=.>X.XR(9KD<<^3-@TRH Z8XH7=@HL=;&PN\93'1M0R
MAR#%,*$O+.O,6Q 0'@AE; [M'93F6#-)^)V%2PEL,@T0UM[;O,KY?89NYO:/
M<LJXY)B!UNR)'71,>[>7D*%$')J(4]'<17T_$K%<H*I3**#+,E\"[T@9<:T_
M-=D:<Q2 0BV(&(<VA7&2PBB#3</9&&6!U6N#B!2"J3@-ML!,JC6>V!V+"M*V
M-YN%<;R@AK<X*[,.G_Q(J2#,>QACX/D*UQH26>5L*CA"]"Q!<Q:?<;@E:36?
M*M),WU7C*YG,KU [+-Y9D)9-^M3D/9H:B U!?E_G8A?Z/@P$59KYCMH(8.=9
M0O2$+Y=LF8_ 1)3@09H'BP5J/'8'W/>$=I7L&W(JWS<@W^\ /5UFMSGVT_MW
MS$P(S1"3JXXQ44[MW$S0Q];RC#\Q9TH/<<E\'B0^KB(N/:,X"(,*J!AU0^3^
M(^&?3M@(%O*-1JT7#AWV*)MVTGGKFI]M%\ZP0$']8_:IP3IBOC=\;&325D\"
MK02-"<JN!(AG?J)\5?E X#0CO:8>DQ(3]3"8:!J:H"/) ]W,0,UJGN^A\0,E
M/I!09"9:.Y]P,^5GDWQ'#$&(9[:ZTTDZ3UNQ\$A@FZ%@**\)L^D$8N)L6,(+
M 3T(\,#/EA]2ZJ HIUII&!N&RDQ?."%I(OG)B.;15!+F/PTWOR0RK=RN?4MA
M$[&?T=#JNP+KODI\'%7,2G(#)_;$-PYJ.I..$W]H#B2FHFS0YM20IO__KUSN
MU3S3^4NEPMY*X7L'[)(/Q2$$?TD(:=#/*I7LE6S[Y/?,N,5/1%O;.=^(]LP[
MV<OE]<9$J_>E7[H_],)]X?US*L7X>N1SG+ZW-G=A";J-] Y!O1Y-C_;Y7OZG
ML16[LBU9L%[1KJ=ZHYTGZ:CQ/@SD$&MQ)+YD:WTTC4.VM^NPGJ+30 M6HE8_
M\6GVK)M@SF+;CI/=^,!]/N9?0\R_9V U'-$"MO/:<;8KSHZSG?NF.WO+?1\,
MJ@!5#K[Z2O#/E3ZU/G@1&5 N8FXO!W*$P_LQMZAL ?-5 KW%^<M^U/VQ/R^_
M5+2^DX^SN=^]7S8#IFZV_X%8^(Z_Z.XYOS[J2^T.V?",/>-W@4$M5@2Z*89-
M7<[_D/E8+^]UZ;XOU4^L*LU:!J><?OZ,,:WJ*EMLQ-\RI$_GQ<,>S+YN?S??
MM\%E[5[U]+=/U>/3T^IQL]FI=IO=5O7JWQ^>7--/@?] @8\Y"VT?L@MSQ-8'
MK,-U_/-H]/-H](V.1D]_6KF-_"K]*;#]VV#Z$^*_ %!+ P04    " !/@/M6
M^]%GYK<+  "O*@  &P   &5A,3@R,SDY97@Y.2TQ7VYE=7)O;VYE+FAT;>U:
M:V\;-Q;]+D#_@4W1( %&LF37:6I[@]J)W+KKV(;MMLA^HV8H#>,9<D)RK&A_
M_9Y+<D9C6\X#2)-=8Q?HVN'P<7D?YYY[Z;W?+E\?O^CW]GZ;[+_"3T;_V[L\
MNCR>O-C;"#_Q=2-^WCLX??6&75R^.9[\X]%,*[?#QJ/*L4M9"LM.Q(*=ZY*K
M) PD[$(8.7N$A5AZ]KGK=EG)S5RJ'4931[O,B?=NP LYQY"1\]SMLBE/K^9&
MURH;I+K09H<M<NG$HQ=[!R\F[W,YE8[]_/-PO+=Q@/N<_1V2I$(Y83X@RF,U
MM=7NMSH=BC@1M=&G2K#7(I,I+]BE2'.%67,I;+_W4IM*&^ZD5FQ?*>R10I@S
MHRMM1<;.ZFDA4W8ZFT$8-6=ZQE[JLL3D"Z?3JV^IV;VC5KE'7U*(^P\\/#VY
M;+:_=];DU>2DWSL[WS\Z/YHD[+54:IBPW^MBR39_3-CF:'.+/?GU^/1@PDXF
M?UW\=70^><H>JXS;?)=]T%BL:ZLG)]QF_-T..WE]^?(I>^)RP1X7V;M:[\)
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M1H$S1+ZQ JGUR/<E??Q_J)/Q_???/ZS@;L_X;C!@AU(4V0YXQ5SL8J-W-17
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MR=W1\DOZB\_P)Z#TEZ+_!5!+ P04    " !/@/M60$FPW"D#  #:"P  $0
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ML&W8+;J@''Q5"[1AJJ:7OP%02P,$%     @ 3X#[5AG2%A?]"@  @(8  !4
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MV]*.YEFTK@$![9J0M(1!@0*Y V$I C0S>8A78/Y%L!B&2TWI!Y:653LJE2Q
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MZ"E\4P1(#FT?U#<*@3%4---YY\#7C3W@WDQ;?.-^N;>OVB/_ U!+ 0(4 Q0
M   ( $^ ^U:WFJ5@_!8  +"@   8              "  0    !E83$X,C,Y
M.2TX:U]N975R;V]N92YH=&U02P$"% ,4    " !/@/M6P\T)12&5  !E&P,
M&@              @ $R%P  96$Q.#(S.3EE>#$M,5]N975R;V]N92YH=&U0
M2P$"% ,4    " !/@/M61K2\"AX)  !)+   &@              @ &+K
M96$Q.#(S.3EE>#4M,5]N975R;V]N92YH=&U02P$"% ,4    " !/@/M6^]%G
MYK<+  "O*@  &P              @ 'AM0  96$Q.#(S.3EE>#DY+3%?;F5U
M<F]O;F4N:'1M4$L! A0#%     @ 3X#[5E,(R-O="P  ,"H  !L
M     ( !T<$  &5A,3@R,SDY97@Y.2TR7VYE=7)O;VYE+FAT;5!+ 0(4 Q0
M   ( $^ ^U9 2;#<*0,  -H+   1              "  >?-  !N;71C+3(P
M,C,P-S(T+GAS9%!+ 0(4 Q0    ( $^ ^U89TA87_0H  ("&   5
M      "  3_1  !N;71C+3(P,C,P-S(T7VQA8BYX;6Q02P$"% ,4    " !/
M@/M60T^5H5,'  #/5P  %0              @ %OW   ;FUT8RTR,#(S,#<R
?-%]P<F4N>&UL4$L%!@     (  @ +0(  /7C      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
